https://trial.medpath.com/news/60b84fd60ccbc754/inovio-pharmaceuticals-completes-bla-submission-for-first-in-class-dna-immunotherapy-ino-3107 2025-12-04T06:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/a348451df56cb62d/santen-and-singapore-eye-research-institute-launch-21-million-collaboration-to-develop-disease-modifying-eye-therapies 2025-12-04T06:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/69d3bf093c0562da/virax-biolabs-advances-post-acute-infection-syndrome-diagnostics-with-completed-uk-trial-recruitment-and-fda-engagement 2025-12-04T06:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/73b23739f4caa844/cardiol-therapeutics-cardiolrx-shows-significant-cardiac-benefits-in-phase-ii-myocarditis-trial 2025-12-04T06:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/14ecec3b40d43189/ltr-pharma-receives-ethics-approval-for-spontan-phase-2-trial-targeting-elderly-erectile-dysfunction-patients 2025-12-04T06:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/1464d8636fe6a1cf/hoth-therapeutics-advances-multi-asset-pipeline-with-phase-2-progress-and-orphan-drug-designation 2025-12-04T06:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/4b28d0f89891a55f/acumen-pharmaceuticals-demonstrates-68-fold-increase-in-brain-delivery-for-alzheimer-s-antibody-using-novel-transferrin-receptor-technology 2025-12-04T06:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/938553d9e052b76a/renerva-receives-fda-approval-for-first-in-human-trial-of-novel-nerve-capping-device-to-prevent-chronic-amputation-pain 2025-12-04T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/9c9dc7c476b85bf0/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-in-preclinical-study 2025-12-04T05:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/5003d895dbecd827/inmune-bio-advances-regulatory-pathways-for-cordstrom-and-xpro1595-programs 2025-12-04T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/d95f38e61cda4764/granata-bio-advances-phase-iii-grace-study-for-investigational-gonadotropin-in-ivf-treatment 2025-12-04T05:57:57+00:00 hourly 0.9 https://trial.medpath.com/news/29f5c2f9bdffce3a/mezzion-secures-key-u-s-patent-for-udenafil-in-fontan-patients-extending-exclusivity-to-early-2040s 2025-12-04T05:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/3a8ede3b0d45e1da/amplia-therapeutics-secures-u-s-patent-protection-for-fak-inhibitor-narmafotinib-through-2040 2025-12-04T05:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/dd5cb5545af3b857/rondo-therapeutics-initiates-first-in-human-trial-of-rndo-564-novel-bispecific-antibody-for-advanced-solid-tumors 2025-12-04T05:55:39+00:00 hourly 0.9 https://trial.medpath.com/news/22d5723d9f7fcca4/archeus-technologies-initiates-first-in-human-trial-of-art-101-psma-targeting-radioligand-therapy-for-metastatic-prostate-cancer 2025-12-04T05:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/723d01bc8d918cb6/fda-grants-expanded-approval-for-eli-lilly-s-jaypirca-in-earlier-line-cll-sll-treatment 2025-12-04T05:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/b79b1fb02ba666cc/sutro-biopharma-initiates-phase-1-trial-of-stro-004-next-generation-tissue-factor-adc-for-advanced-solid-tumors 2025-12-04T05:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/c1be79c107d08a73/armr-sciences-initiates-first-human-trials-for-fentanyl-vaccine-in-early-2025 2025-12-04T05:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/39caa15c414bfdee/polypid-receives-fda-support-for-d-plex100-nda-submission-following-positive-pre-nda-meeting 2025-12-04T05:54:25+00:00 hourly 0.9 https://trial.medpath.com/news/e7261ef19e875b1a/muvon-therapeutics-reports-breakthrough-phase-2-results-for-muscle-cell-based-stress-urinary-incontinence-therapy 2025-12-04T05:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/42907702b5018a18/hemophilia-gene-therapies-face-market-struggles-despite-scientific-promise 2025-12-04T05:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/15f2613656cea87f/pacira-s-cryoneurolysis-device-shows-superior-pain-relief-over-radiofrequency-ablation-in-chronic-low-back-pain-study 2025-12-04T05:53:23+00:00 hourly 0.9 https://trial.medpath.com/news/8b6ddd8ba796363e/ema-grants-conditional-marketing-authorization-for-immunitybio-s-anktiva-in-bladder-cancer 2025-12-04T05:53:18+00:00 hourly 0.9 https://trial.medpath.com/news/a13f8b6db35198a5/natera-s-signatera-shows-superior-performance-in-lymphoma-detection-at-ash-2025 2025-12-04T05:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/1366411b3e400f7c/strm-bio-secures-8-4m-arpa-h-contract-to-develop-novel-extracellular-vesicle-platform-for-in-vivo-car-t-cell-engineering 2025-12-04T05:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/0b46b273f4751c3b/onco3r-therapeutics-reports-positive-phase-1-data-for-novel-sik3-inhibitor-o3r-5671-in-autoimmune-disease-treatment 2025-12-04T05:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/abdd5bce22402d10/taiwan-approves-nt-100-million-gene-therapy-for-rare-aadc-deficiency-amid-coverage-debate 2025-12-04T05:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/b1c3e5a9c3f31120/belite-bio-s-tinlarebant-achieves-35-7-reduction-in-lesion-growth-in-first-successful-phase-3-trial-for-stargardt-disease 2025-12-04T05:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/962159b104b11f49/university-of-virginia-launches-clinical-trial-for-new-covid-19-treatment-targeting-outpatients 2025-12-04T05:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/78746622af8ae1ff/australia-issues-new-safety-warnings-for-glp-1-drugs-following-reports-of-suicidal-thoughts 2025-12-04T05:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/f5b8640c903ad0c1/bausch-lomb-partners-with-ripple-therapeutics-to-develop-polymer-free-sustained-release-ophthalmic-implants 2025-12-04T05:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/10021895f646c92f/jasper-therapeutics-reports-positive-phase-1b-data-for-briquilimab-in-asthma-completes-beacon-study-investigation 2025-12-04T05:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/f375ff6369367649/roche-receives-fda-clearance-for-15-minute-point-of-care-bordetella-pcr-test 2025-12-04T05:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/ca6ce54505229312/two-companies-launch-competing-glp-1-clinical-trials-for-feline-weight-management 2025-12-04T05:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/a5b7c259ee1c2c8e/akiram-therapeutics-advances-cd44v6-targeted-radiotherapy-akir001-with-cohort-2b-clearance-and-journal-publication 2025-12-04T05:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/ee16b69273415e6e/fda-issues-alert-after-seven-deaths-linked-to-abbott-freestyle-libre-3-glucose-monitor-defects 2025-12-04T05:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/c0973309ffa0ca70/glp-1-pricing-agreements-open-market-for-new-obesity-drug-competitors 2025-12-04T05:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/90e369764301444b/lotus-pharma-submits-first-regulatory-application-for-vizz-presbyopia-treatment-in-south-korea 2025-12-04T05:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/67af1d855b136c91/4d-path-s-ai-platform-predicts-chemotherapy-response-in-triple-negative-breast-cancer-using-standard-biopsy-images 2025-12-04T05:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/31c65e9319585af0/outlook-therapeutics-awaits-critical-fda-decision-on-first-ophthalmic-bevacizumab-for-wet-amd-by-december-31 2025-12-04T05:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/0c1414aa1f3147d9/automated-lung-organoid-production-breakthrough-promises-to-accelerate-respiratory-drug-development 2025-12-04T05:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/781cde7631e6fead/pentixapharm-receives-fda-guidance-for-phase-3-panda-study-of-68ga-pentixafor-in-primary-aldosteronism 2025-12-04T05:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/f7159912a3368e3c/excelsior-sciences-secures-95-million-to-revolutionize-ai-driven-small-molecule-drug-discovery 2025-12-04T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/b4787652f999a3da/quadriga-biosciences-reports-promising-phase-iia-results-for-qbs72s-in-breast-cancer-leptomeningeal-disease 2025-12-04T05:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/9784dcd968630d12/protara-s-tara-002-shows-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T05:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/4d414b71d1b7a05b/relmada-therapeutics-presents-promising-6-month-data-for-ndv-01-bladder-cancer-treatment-at-urologic-oncology-meeting 2025-12-04T05:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/3e0898465634140d/illumina-and-myome-partner-to-advance-200-billion-healthcare-savings-through-ai-driven-genomic-medicine 2025-12-04T05:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/330697e150db09e0/who-approves-olastrocel-as-international-name-for-creative-medical-s-lead-cell-therapy-celz-201 2025-12-04T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/b928f32ab34f43ed/fda-grants-accelerated-approval-to-otsuka-s-voyxact-for-iga-nephropathy-first-april-targeting-therapy 2025-12-04T05:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/de436cbf66d70152/cms-approves-47-payment-increase-for-optical-genome-mapping-in-blood-cancer-diagnostics 2025-12-04T05:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/2d5a6ca3c19a32dd/two-novel-alzheimer-s-therapies-advance-in-phase-2-trials-oral-pri-002-and-trem2-targeting-vhb937 2025-12-04T05:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/e1ac8f934a8295a3/federal-appeals-court-overturns-41-million-patent-verdict-against-daiichi-sankyo-s-enhertu-adc 2025-12-04T05:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/9f7b3d4a982e2634/fda-approves-300mg-strength-of-celltrion-s-omlyclo-first-interchangeable-biosimilar-to-xolair 2025-12-04T05:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/49bc46a840896276/jaguar-health-seeks-ema-approval-for-canalevia-in-european-union-to-treat-general-diarrhea-in-dogs 2025-12-04T05:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/263a51b31bc6f836/samsung-bioepis-secures-european-approval-for-byooviz-pre-filled-syringe-formulation 2025-12-04T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/a51210158c857ba8/ensysce-biosciences-secures-extended-patent-protection-for-mpar-overdose-prevention-technology-through-2042 2025-12-04T05:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/10dbcea02915c48f/strand-therapeutics-appoints-former-nimbus-ceo-jeb-keiper-to-board-as-company-advances-programmable-mrna-platform 2025-12-04T05:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/8b9f2ee446606f50/china-s-pharmaceutical-patent-linkage-system-shows-growing-judicial-maturity-after-four-years-of-operation 2025-12-04T05:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/0489ba7e9d3ecef4/fda-clears-first-in-class-vectorized-antibody-trial-for-als-targeting-tdp-43-pathology 2025-12-04T05:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/a30280df0d787f3a/jupiter-neurosciences-advances-jotrol-into-phase-2a-parkinson-s-trial-following-fda-clearance 2025-12-04T05:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/3617b29a4047b38b/leqembi-shows-measurable-target-engagement-with-alzheimer-s-protofibrils-in-cerebrospinal-fluid 2025-12-04T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/316a24580457b376/moderna-faces-regulatory-headwinds-as-fda-signals-stricter-vaccine-approval-standards 2025-12-04T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/3e4f9bea524107a0/nrx-pharmaceuticals-expands-nrx-101-development-to-include-combination-therapy-with-transcranial-magnetic-stimulation-for-depression 2025-12-04T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/27b0a7ff93d6fdc7/cosmo-s-clascoterone-5-topical-solution-achieves-breakthrough-results-in-phase-iii-male-pattern-hair-loss-trials 2025-12-04T05:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/ee7b57ef400bd155/avecho-biotechnology-secures-us-and-eu-patent-protection-for-cbd-insomnia-treatment-through-2040 2025-12-04T05:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/e0e7c490a660d578/aob-pharma-secures-ema-pediatric-investigation-plan-approval-for-b244-atopic-dermatitis-treatment-with-topical-corticosteroid-waiver 2025-12-04T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/0737b98c7f671f59/triana-biomedicines-secures-120m-series-b-to-advance-alk-targeted-molecular-glue-degrader-for-lung-cancer 2025-12-04T05:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/e0ef9cb78f68baba/paradigm-trial-shows-venetoclax-azacitidine-superior-to-intensive-chemotherapy-in-newly-diagnosed-aml 2025-12-04T05:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/96d20dcf09344fce/citizen-health-and-ucb-launch-strategic-partnership-to-accelerate-epilepsy-and-rare-disease-drug-development-using-ai 2025-12-04T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/edd7d4addd053eda/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-12-04T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/0d930fe46fd5b0e0/greenwich-lifesciences-completes-enrollment-in-non-hla-a-02-arm-of-phase-iii-flamingo-01-trial-for-breast-cancer-prevention 2025-12-04T05:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/ff4faab3cf1e87ee/abemaciclib-monotherapy-shows-promise-after-cdk4-6-inhibitor-failure-in-hr-her2-breast-cancer 2025-12-04T05:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/6d92c9c5b0d174b5/alkeus-pharmaceuticals-appoints-carlos-quezada-ruiz-as-chief-medical-officer-to-lead-stargardt-disease-drug-development 2025-12-04T05:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/62c81a1b93e3d7f1/fda-approves-amneal-s-generic-cyclosporine-eye-drops-for-dry-eye-disease-treatment 2025-12-04T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/876c5a6720feac7c/biofrontera-submits-fda-application-for-ameluz-pdt-in-superficial-basal-cell-carcinoma-treatment 2025-12-04T05:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/27f1220c283e0f70/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma-following-landmark-aquila-trial-results 2025-12-04T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b0daa2b4219ad35/zynlonta-plus-glofitamab-achieves-89-8-response-rate-in-relapsed-refractory-dlbcl-trial 2025-12-04T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/1e23b119db31069a/alzecure-receives-eur2-5-million-eu-grant-to-advance-phase-2a-trial-of-novel-alzheimer-s-drug-acd856 2025-12-04T05:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/7dbd6f8afa1da1e1/harmony-biosciences-to-present-phase-3-epx-100-data-for-dravet-syndrome-at-aes-annual-meeting 2025-12-04T05:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/126eeec2dd11b2f7/elevar-s-rivoceranib-camrelizumab-combination-shows-significant-survival-benefit-in-phase-3-liver-cancer-trial 2025-12-04T05:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/949382d327acd64d/savara-secures-european-patent-protection-for-molbreevi-through-2041-strengthening-ip-portfolio-for-rare-lung-disease-therapy 2025-12-04T05:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/f24bb758cf95dc62/sagent-pharmaceuticals-partners-with-provepharm-to-launch-bludigo-first-fda-approved-injectable-indigo-carmine-diagnostic-dye 2025-12-04T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/f22d45fabad0ad56/kura-oncology-receives-135-million-milestone-payment-as-komzifti-achieves-first-commercial-sale 2025-12-04T05:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/dc75bc4ac713d1d1/pharvaris-reports-positive-phase-3-results-for-oral-hae-treatment-deucrictibant 2025-12-04T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/0497558cfed21199/latus-bio-receives-fda-ind-clearance-for-lts-101-gene-therapy-to-treat-fatal-cln2-disease-in-children 2025-12-04T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/ae3a06a3e7cf2677/immuron-secures-us-department-of-defense-award-for-novel-oral-therapeutics-against-military-priority-pathogens 2025-12-04T05:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/acf014dc7449556d/pedmark-shows-significant-reduction-in-cisplatin-induced-hearing-loss-in-japanese-pediatric-cancer-study 2025-12-04T05:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/da27c38e78ee7a84/incannex-healthcare-receives-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T05:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/05957e55f48ab718/iolyx-therapeutics-secures-280m-partnership-with-laboratoires-thea-for-autoimmune-dry-eye-treatment 2025-12-04T05:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/73c256ceb2006942/amneal-secures-fda-approval-for-generic-albuterol-inhaler-marking-second-respiratory-win-in-q4-2025 2025-12-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd54c47976eeda58/silexion-therapeutics-receives-german-regulatory-approval-for-phase-2-3-pancreatic-cancer-trial-design 2025-12-04T05:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/6c6d17b669a8c8d9/abbvie-presents-breakthrough-data-at-ash-2025-demonstrating-significant-advances-in-blood-cancer-treatment 2025-12-04T05:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/507bcbfd5ca7ef0e/black-diamond-therapeutics-to-present-phase-2-silevertinib-results-for-egfr-mutant-nsclc 2025-12-04T05:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/28adc5e682d56b3b/delhi-high-court-allows-dr-reddy-s-to-export-semaglutide-challenges-novo-nordisk-patent-validity 2025-12-04T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/919b3423ecfa6e43/tiakis-biotech-advances-tiprelestat-to-phase-ii-trial-for-pulmonary-arterial-hypertension-following-positive-safety-data 2025-12-04T05:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/8c1b72ec85767aad/quetzal-therapeutics-initiates-phase-iii-trial-of-oral-arsenic-trioxide-qtx-2101-for-acute-promyelocytic-leukemia 2025-12-04T05:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/05b730d77ae8fbf9/uk-approves-tisotumab-vedotin-for-recurrent-cervical-cancer-demonstrating-30-reduction-in-death-risk 2025-12-04T05:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/2fcd31cef1980ff9/fda-approves-wave-of-oncology-drugs-and-biosimilars-in-november-2025-expanding-treatment-access 2025-12-04T05:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/f78764e5cfbe7374/fda-approves-ziftomenib-first-in-class-targeted-therapy-for-npm1-mutated-acute-myeloid-leukemia 2025-12-04T05:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/ef1933d6b64f70fd/bristol-myers-squibb-delays-cobenfy-alzheimer-s-psychosis-trial-results-to-2026-following-site-irregularities 2025-12-04T05:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/3ea5865eb6c71831/vandria-s-vna-318-shows-promising-phase-1-results-with-novel-dual-action-mechanism-for-alzheimer-s-disease 2025-12-04T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/cf5751acefef1859/polaritybio-completes-phase-iii-trial-of-skinte-for-diabetic-foot-ulcers-targets-first-bla-approval-since-1997 2025-12-04T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/9b3fb26b7d58828f/ai-powered-remote-monitoring-shows-promise-for-reducing-patient-burden-in-clinical-trials 2025-12-04T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/544ed28bbcf9ea5e/roche-s-trontinemab-shows-92-amyloid-clearance-success-in-alzheimer-s-mid-stage-trial 2025-12-04T05:21:14+00:00 hourly 0.9 https://trial.medpath.com/news/f0f1937d44890942/fda-chief-claims-covid-19-vaccines-linked-to-10-pediatric-deaths-sparking-expert-criticism-and-market-decline 2025-12-04T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/56078aa74df8226f/us-house-passes-bipartisan-bill-to-reauthorize-fda-s-rare-pediatric-disease-priority-review-voucher-program 2025-12-04T05:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/520a9aa4a5042a23/roche-s-trontinemab-shows-92-success-rate-in-clearing-alzheimer-s-amyloid-plaques 2025-12-04T05:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/9d1affd229725983/fda-deploys-agentic-ai-across-agency-to-accelerate-drug-reviews-and-modernize-regulatory-workflows 2025-12-04T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/610904a8d3014ddc/bayer-proposes-7-25-billion-roundup-settlement-as-trump-administration-backs-supreme-court-appeal 2025-12-03T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/276bf2aba0c2e337/medicus-pharma-appoints-carolyn-bonner-as-cfo-while-advancing-multiple-clinical-programs 2025-12-03T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/98feb3419581eb7c/phase-i-trial-evaluates-pevonedistat-capecitabine-oxaliplatin-combination-for-advanced-gastric-cancer 2025-12-03T08:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/b1705f932997f68c/imvax-plans-fda-discussions-for-glioblastoma-therapy-despite-missing-primary-endpoint 2025-12-03T06:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/7ffcc68bd3796a82/ai-driven-study-identifies-z-endoxifen-as-promising-therapeutic-candidate-for-glioblastoma 2025-12-03T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/cb889fe6151a0ee9/curi-bio-raises-10m-series-b-to-scale-human-ipsc-platforms-for-drug-discovery 2025-12-03T06:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/4ba4f24042f705ac/diagnostear-partners-with-alyatec-for-clinical-validation-of-revolutionary-red-eye-diagnostic-test 2025-12-03T06:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/0a9975fbe8e2877e/amgen-secures-fda-approval-for-imdelltra-in-small-cell-lung-cancer-as-pipeline-advances-drive-growth 2025-12-03T06:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/56abe275dbf8ea80/fda-grants-orphan-drug-designation-to-birchbiomed-s-fs2-for-idiopathic-pulmonary-fibrosis-treatment 2025-12-03T06:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/06847fc644d476b6/engene-s-detalimogene-selected-for-fda-manufacturing-pilot-program-to-accelerate-bladder-cancer-gene-therapy-development 2025-12-03T06:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/703446c61fb65723/uk-secures-zero-tariff-us-pharmaceutical-deal-with-25-increase-in-nhs-medicine-investment 2025-12-03T06:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/a9201804fa92f62e/electra-therapeutics-advances-ela026-in-pivotal-trial-for-rare-blood-disorder-shlh 2025-12-03T06:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/6a744b8309b2e8c3/fda-issues-draft-guidance-to-reduce-primate-testing-for-monoclonal-antibody-therapies 2025-12-03T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/a674a6c51c5d89ed/antengene-receives-nmpa-approval-for-phase-ib-ii-study-of-atg-022-cldn18-2-adc-in-combination-with-pembrolizumab-for-gastric-cancer 2025-12-03T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/347d31ff1709b90e/ajovy-becomes-first-cgrp-antagonist-approved-for-pediatric-migraine-prevention-following-positive-space-trial-results 2025-12-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/11fe4f14e0552843/tang-capital-management-invests-56-8-million-in-celcuity-following-positive-phase-3-gedatolisib-results 2025-12-02T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee44caa1ff762c7c/mirum-pharmaceuticals-initiates-phase-ii-trial-of-mrm-3379-for-fragile-x-syndrome 2025-12-02T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6d4a166a2d62c85/breast-cancer-index-test-shows-promise-for-identifying-low-risk-premenopausal-patients-who-may-avoid-aggressive-therapy 2025-12-02T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/95f1869ae704827c/bionexus-gene-lab-launches-vitaguard-mrd-platform-across-southeast-asia-to-challenge-3000-legacy-cancer-monitoring-systems 2025-12-02T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/97ac5c2023db71b3/3d-printed-corneal-implant-restores-sight-to-legally-blind-patient-in-world-first-surgery 2025-12-02T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/68cc09d80181eb57/neurothera-labs-pursues-quantum-computing-acquisition-to-accelerate-cns-drug-development 2025-12-02T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/47ebe4602de44b4f/nice-approves-papillon-brachytherapy-for-nhs-use-in-early-stage-rectal-cancer 2025-12-02T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/3c9aeaa3ae79e1f3/lynk-pharmaceuticals-receives-fda-ind-approval-for-brain-penetrant-tyk2-inhibitor-lnk01006-targeting-neuroinflammatory-diseases 2025-12-02T05:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/5c6b9b2248baf25e/three-fda-approvals-in-three-months-transform-hereditary-angioedema-treatment-landscape-in-2025 2025-12-02T03:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/14b9305b5cc410a2/belite-bio-raises-350-million-to-advance-retinal-disease-therapies-toward-commercialization 2025-12-02T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/bef687f1cb19a2f4/aptargroup-acquires-brazilian-oral-dosing-specialist-sommaplast-to-expand-pharmaceutical-packaging-capabilities 2025-12-01T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/92002a6b2cadd23f/combination-immunotherapy-shows-promise-for-hiv-control-after-art-discontinuation 2025-12-01T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/3b4fa2f791af80e2/apimeds-pharmaceuticals-merges-with-ai-driven-digital-asset-company-mindwave-in-100m-deal 2025-12-01T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/a5c4a3ac0e5e2a99/eib-and-angelini-ventures-launch-eur150-million-european-biotech-investment-initiative 2025-12-01T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/a64c9bfa00d4cc06/juniper-biosciences-secures-40-million-seed-funding-to-advance-radiopharmaceutical-pipeline 2025-12-01T17:39:59+00:00 hourly 0.9 https://trial.medpath.com/news/163c6550059b8e58/faron-pharmaceuticals-appoints-former-astrazeneca-executive-as-cfo-ahead-of-bexmarilimab-registrational-study 2025-12-01T17:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/b36fc6003e36e7d1/kiora-pharmaceuticals-secures-new-patent-for-kio-104-formulations-extending-market-protection-to-2043 2025-12-01T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/0dcba7400ee14377/salarius-pharmaceuticals-partners-with-texas-biomed-to-test-ai-designed-antiviral-against-h5n1-avian-flu 2025-12-01T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/c9636ad2ee903b25/recursion-to-present-updated-clinical-data-from-phase-1b-2-trial-of-rec-4881-in-familial-adenomatous-polyposis 2025-12-01T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/104e62709d2df37e/promis-neurosciences-validates-plasma-ptau-as-early-predictor-for-alzheimer-s-drug-development 2025-12-01T17:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/0090eca8c2cfa6a7/neonc-s-neo100-shows-enhanced-brain-tumor-efficacy-when-combined-with-ultrasound-in-ai-driven-study 2025-12-01T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/787d0ea70e68c0a7/regeneron-partners-with-tessera-in-275m-gene-editing-deal-for-alpha-1-antitrypsin-deficiency-treatment 2025-12-01T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/8ed1788d80d507bb/akebia-therapeutics-establishes-rare-kidney-disease-pipeline-with-two-novel-therapeutic-candidates 2025-12-01T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/d5184eed604bbac8/morphocell-technologies-completes-50-million-series-a-to-advance-liver-disease-therapeutics 2025-12-01T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/26a687133762e147/keynote-811-trial-shows-pembrolizumab-combination-improves-response-rates-in-her2-positive-gastric-cancer 2025-12-01T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/df6f74c309b11955/oncoprecision-s-first-in-class-cd64-targeting-adc-onc001-selected-for-oral-presentation-at-ash-2025 2025-12-01T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/1f976b2274eef7a5/gsk-presents-long-term-data-supporting-belantamab-mafodotin-and-momelotinib-for-blood-cancers-at-ash-2024 2025-12-01T17:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/9729aa2856b6d4ae/mabwell-s-anti-st2-antibody-9mw1911-shows-over-40-reduction-in-severe-copd-exacerbations-in-phase-iia-trial 2025-12-01T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/b8f82925c96ef968/saga-diagnostics-presents-breakthrough-mrd-data-at-sabcs-2025-demonstrating-100-sensitivity-in-breast-cancer-detection 2025-12-01T17:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/e837fe75fc7bfd65/solid-biosciences-secures-fda-rare-pediatric-disease-designation-for-novel-friedreich-s-ataxia-gene-therapy 2025-12-01T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/d6866003a74b67f0/merck-receives-fda-fast-track-designation-for-novel-alzheimer-s-tau-targeting-antibody-mk-2214 2025-12-01T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/dd1f14508d170036/who-approves-tazbentetol-as-international-name-for-spinogenix-s-first-in-class-synaptic-regenerative-therapy 2025-12-01T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/568ddcf3210cedc8/fda-approves-isopsa-blood-test-to-reduce-unnecessary-prostate-biopsies 2025-12-01T17:21:48+00:00 hourly 0.9 https://trial.medpath.com/news/1d6c8f9ea12cedc3/jacobio-s-kras-g12c-combination-therapy-achieves-71-response-rate-in-first-line-nsclc-trial 2025-12-01T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/82a5f1d595d9a0bd/lenz-therapeutics-and-lotus-pharmaceutical-submit-vizz-for-presbyopia-treatment-approval-in-south-korea 2025-12-01T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/87f4b703f59c6b57/lilly-launches-five-year-real-world-trial-of-tirzepatide-in-uk-primary-care-settings 2025-12-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/bada23b859224cad/glial-cell-immune-networks-drive-neuroinflammation-in-glaucomatous-optic-nerve-degeneration 2025-12-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6e8a2166e9f3612/bridgebio-pharma-advances-three-potential-first-in-class-therapies-for-rare-diseases 2025-12-01T15:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e756f0cba7f64b7/nyxoah-secures-major-cms-reimbursement-increase-for-genio-sleep-apnea-device 2025-12-01T14:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/331aa42577b9b496/mendus-achieves-large-scale-gmp-manufacturing-milestone-for-vididencel-cell-therapy-in-aml-and-cml 2025-12-01T13:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/35a62031ff2e53ba/protego-biopharma-raises-130m-to-advance-novel-protein-stabilization-approach-for-al-amyloidosis 2025-12-01T13:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/6f2236e18e1278ed/compass-therapeutics-advances-oncology-pipeline-with-pivotal-tovecimig-data-expected-q1-2026 2025-12-01T13:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/16b492c9262cbdd0/abbvie-s-atogepant-shows-superior-efficacy-in-phase-3-eclipse-trial-for-acute-migraine-treatment 2025-12-01T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/66e06887174ca0f8/ideaya-biosciences-receives-fda-clearance-for-first-in-class-bispecific-adc-ide034-targeting-multiple-solid-tumors 2025-12-01T13:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/d8b47802e4e44c20/wockhardt-shares-surge-19-following-fda-acceptance-of-zaynich-antibiotic-application 2025-12-01T13:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/ac22e559a5f6a9f2/zentiva-launches-first-biosimilar-monoclonal-antibody-across-eu-markets 2025-12-01T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/7ec8edc7e54cf748/injectable-hiv-treatment-shows-promise-in-african-trial-offering-hope-for-improved-adherence 2025-12-01T09:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/4734fc1d2452e0c3/enlivex-therapeutics-secures-212-million-funding-for-osteoarthritis-therapy-development-and-digital-asset-strategy 2025-12-01T09:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/25c1028a02055fa7/theia-ventures-leads-pre-seed-funding-for-lemnisca-s-ai-driven-biomanufacturing-platform 2025-12-01T09:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/54610a8fb913bfc3/menin-inhibitors-show-promise-as-targeted-therapy-for-aggressive-kmt2a-rearranged-acute-leukemia 2025-12-01T09:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/4bea43340bc93466/australian-regulator-updates-safety-warnings-for-glp-1-drugs-over-suicidal-ideation-risk 2025-12-01T05:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/e2610b6921fe7fb3/nitrous-oxide-shows-promise-as-rapid-acting-treatment-for-treatment-resistant-depression 2025-12-01T05:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/2966c2fb75f2348d/nevada-health-centers-partners-with-javara-to-expand-clinical-trial-access-including-norovirus-vaccine-study 2025-12-01T05:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/1246fe56af38630b/zuellig-pharma-opens-advanced-clinical-trial-support-innovation-center-in-south-korea 2025-12-01T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/73d33021d5dd0ddd/nanoviricides-submits-orphan-drug-application-for-nv-387-measles-treatment-as-cases-surge-in-us 2025-12-01T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c755867bf30b694/clinical-trial-data-managers-lose-12-hours-weekly-to-manual-tasks-raising-quality-concerns 2025-12-01T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/12cbe8cf619e269e/scisparc-acquires-muse-endoscopy-patent-portfolio-to-enter-2-5-billion-gerd-device-market 2025-12-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5a04ef1490685df/avandra-health-acquires-datcard-systems-and-sorna-corporation-to-create-world-s-largest-medical-imaging-platform 2025-11-30T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/a3f7c3b50899686b/gut-brain-axis-emerges-as-key-pathway-in-parkinson-s-disease-pathogenesis 2025-11-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fc0db651b1a7040f/cereno-scientific-secures-sek-665-million-financing-to-advance-rare-disease-pipeline-through-2027 2025-11-30T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/2a2732ceeaf19192/nigeria-s-niprd-and-futh-lafia-partner-to-advance-local-vaccine-and-drug-development 2025-11-30T05:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/4834f844bb43230e/ace2-decoy-receptor-shows-promise-against-multiple-sars-cov-2-variants-in-new-study 2025-11-29T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/14e3ed23bfee3fdd/single-2-ml-mirikizumab-injection-demonstrates-bioequivalence-to-two-1-ml-doses-in-healthy-participants 2025-11-29T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/5f35bcf5bf1e47de/ultrasound-activated-nanocatalysts-trigger-novel-cancer-cell-death-mechanism-in-preclinical-study 2025-11-29T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/dbeec7e3de50ae58/fda-internal-memo-links-10-pediatric-deaths-to-covid-19-vaccination-citing-myocarditis-concerns 2025-11-29T14:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/0de4a70c241f7570/zura-bio-advances-tibulizumab-phase-2-trials-with-139-million-cash-runway-through-2027 2025-11-29T14:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/b61dae5ce9d568d6/novel-hdac2-inhibitor-shows-promise-for-cancer-therapy-despite-acute-toxicity-concerns 2025-11-29T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/7e7dc6a802d6fac3/dea-finalizes-significant-increases-in-psychedelic-production-quotas-for-2026-to-support-ptsd-and-depression-research 2025-11-29T01:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/86424f3a852e9b1d/terumo-bct-partners-with-santersus-to-advance-novel-blood-purification-technology-for-sepsis-treatment 2025-11-29T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/51ee6dbffdf5f085/australian-researchers-identify-romidepsin-as-breakthrough-treatment-for-relapsed-neuroblastoma 2025-11-29T01:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/179b20f38f08a5cf/hanmi-pharmaceutical-s-hm16390-shows-dual-mechanism-for-enhanced-cancer-immunotherapy-safety-and-efficacy 2025-11-28T21:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/6bdc25bb7b2050e4/real-world-meta-analysis-confirms-galcanezumab-efficacy-in-migraine-prevention-across-3859-patients 2025-11-28T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/bafe0b0beb0cc3bb/pasithea-therapeutics-secures-60-million-funding-to-advance-mek-inhibitor-for-neurofibromatosis-treatment 2025-11-28T17:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/60d81ef6bd24bb71/canada-s-drug-agency-recommends-public-reimbursement-for-skyrizi-in-ulcerative-colitis 2025-11-28T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/80de7e2e13f48641/novel-biopolymeric-nanocarrier-system-targets-cd44-receptors-for-enhanced-irinotecan-delivery-in-skin-cancer-treatment 2025-11-28T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/14e6687fa4a5de62/veraxa-biotech-s-nasdaq-listing-back-on-track-after-us-government-shutdown-delays 2025-11-28T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/6493a5ea0041ab25/ge-healthcare-receives-ce-mark-for-revolutionary-total-body-pet-ct-system-and-digital-spect-ct-platform 2025-11-28T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/3f8102688cd1a62b/cytiva-and-veeda-lifesciences-establish-host-cell-protein-analysis-center-in-india-to-support-biopharmaceutical-development 2025-11-28T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/ee19c79c166c7ae2/china-s-first-dual-indication-car-t-therapy-receives-nmpa-approval-for-large-b-cell-lymphoma 2025-11-28T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/2ca6bd07a27df5f6/profound-medical-launches-ai-powered-bph-module-and-expands-global-reach-through-strategic-partnerships 2025-11-28T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/79957ebcbb7162db/ephb4-targeted-car-t-cell-therapy-enters-phase-i-trial-for-solid-tumors 2025-11-28T13:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/6c9f046d78647c89/researchers-engineer-mrna-modified-allogeneic-mscs-for-enhanced-t-cell-immunotherapy 2025-11-28T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/1226214e4dfc3fc5/lmu-researchers-develop-ai-powered-platform-to-accelerate-rna-drug-carrier-design 2025-11-28T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/01ec2c5fdaf5c5f2/gene-solutions-launches-ai-powered-spot-mas-multi-cancer-screening-platform-in-taiwan 2025-11-28T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/881522ec2bcab972/china-approves-first-domestic-il-23p19-antibody-for-psoriasis-treatment 2025-11-28T13:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/98866231df08c21b/innocare-initiates-global-phase-ii-trial-of-tyk2-inhibitor-soficitinib-for-prurigo-nodularis-treatment 2025-11-28T09:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/cd8d9e780b89f813/pre-transplant-treg-expansion-therapy-shows-promise-for-reducing-gvhd-risk-in-blood-cancer-patients 2025-11-28T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/73a8e632f3bed4cf/fzocus-1-trial-shows-fuzuloparib-maintenance-therapy-improves-survival-in-advanced-ovarian-cancer 2025-11-28T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/95bad9151bfc7726/bone-metastasis-treatment-pipeline-shows-robust-development-with-10-companies-advancing-novel-therapies 2025-11-28T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/08f6210168963dd5/ge-healthcare-receives-fda-authorization-for-ai-powered-3d-mammography-technology 2025-11-28T01:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/424fcea214cfd904/northwestern-researchers-develop-reengineered-hpv-vaccine-that-trains-t-cells-to-hunt-cancer 2025-11-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eff20e94a5075f04/transgene-secures-eur105-million-to-advance-personalized-cancer-vaccine-platform 2025-11-27T21:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/8457a525add3eb71/stanford-researchers-demonstrate-cartilage-regeneration-through-gerozyme-inhibition-in-preclinical-studies 2025-11-27T21:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/a152626c34612e3e/mbx-biosciences-advances-toward-phase-3-trial-despite-major-investor-exit 2025-11-27T20:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/8d95917736898738/maibe-and-leniobio-form-strategic-partnership-to-accelerate-ai-driven-monoclonal-antibody-discovery 2025-11-27T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/244f147137df5450/moderna-s-mrna-norovirus-vaccine-enters-phase-3-trial-at-newcastle-hospitals 2025-11-27T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/7744e4a60342cc78/neuraxpharm-and-mjn-neuro-launch-ai-powered-wearable-device-for-early-epileptic-seizure-detection 2025-11-27T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/1a7212ed5924e256/efgartigimod-shows-promise-in-treating-immune-checkpoint-inhibitor-associated-myocarditis-and-myasthenia-gravis 2025-11-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5f4925106cd38701/monthly-tezepelumab-injection-enables-severe-asthma-patients-to-discontinue-daily-steroids 2025-11-27T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/38d82a577c6ba611/mendus-reports-positive-2-year-follow-up-data-for-vididencel-immunotherapy-in-high-risk-ovarian-cancer 2025-11-27T13:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/7c935860915ee277/patronus-biotech-secures-gates-foundation-grant-for-novel-multi-stage-malaria-vaccine-development 2025-11-27T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/5dad62ea4602b99c/fda-grants-medivir-s-miv-711-orphan-drug-designation-for-osteogenesis-imperfecta-treatment 2025-11-27T13:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/fa99548713496905/gan-lee-pharmaceuticals-launches-phase-3-trial-for-once-monthly-glp-1-receptor-agonist-bofanglutide 2025-11-27T13:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/3f4e6f2c45625c63/ema-grants-orphan-drug-designation-to-kedrion-s-ceruloplasmin-treatment-for-rare-iron-metabolism-disorder 2025-11-27T13:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/8e1d35a3249f31eb/fda-withdraws-asbestos-testing-rule-for-talc-cosmetics-plans-revised-proposal 2025-11-27T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/5eb6d5fb802ba369/delphx-capital-markets-completes-c-112000-private-placement-to-support-structured-products-development 2025-11-27T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/209b5d4d2501cf0d/sk-biopharmaceuticals-licenses-wt-7695-radiopharmaceutical-targeting-ca9-for-solid-tumors 2025-11-27T10:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/2f8678523bbbad73/fda-backed-anti-aging-drug-for-dogs-targets-2026-launch-following-efficacy-approval 2025-11-27T08:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/10f46b30fce41be1/chinese-developed-her2-targeting-adc-tqb2102-achieves-77-complete-response-rate-in-phase-ii-breast-cancer-trial 2025-11-27T08:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/6cde99a6411271ec/mhra-approves-inavolisib-for-advanced-hr-positive-her2-negative-breast-cancer 2025-11-27T05:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/ee3ca735f245afd9/federal-r-d-budget-cuts-threaten-us-biomedical-innovation-leadership 2025-11-27T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/8d191e93b4fc453b/heartbeam-pursues-multiple-regulatory-paths-after-fda-rejects-12-lead-ecg-synthesis-software-application 2025-11-27T01:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/e7e8ad82439b5ed5/fda-grants-fast-track-designation-to-zotiraciclib-for-idh-mutant-recurrent-high-grade-glioma 2025-11-27T01:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/17996e270bbd3285/imugene-partners-with-jw-therapeutics-to-develop-first-in-class-car-t-combination-for-solid-tumors 2025-11-27T01:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/241b0ff31cb1d5ec/arrowhead-pharmaceuticals-soars-23-on-fda-approval-of-redemplo-for-rare-genetic-disease 2025-11-27T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/188a5e164d1ff669/zetagen-therapeutics-raises-12-9m-in-oversubscribed-series-b1-round-following-promising-phase-2a-results-for-breast-cancer-treatment 2025-11-27T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/3b136d9d9cd7d723/kinase-inhibitors-discovered-to-trigger-widespread-protein-degradation-beyond-traditional-inhibition 2025-11-27T01:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/81bc7e25aeb31ca7/engasertib-shows-promise-in-first-controlled-trial-for-hereditary-hemorrhagic-telangiectasia 2025-11-27T01:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/db5250c27ffb9fc8/valneva-consolidates-french-operations-closes-nantes-facility-amid-regulatory-setbacks 2025-11-26T21:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/c59f2bf2e2869cfd/missing-prkci-gene-enhances-immunotherapy-response-in-lung-adenocarcinoma-through-senescent-cell-activation 2025-11-26T21:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/e8861851e0e6b32f/piramal-pharma-solutions-achieves-full-regulatory-compliance-for-nitrosamine-impurities 2025-11-26T21:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/729ec9e1f123ea7f/arrowhead-pharmaceuticals-achieves-fda-approval-for-rodemplo-reports-strong-financial-turnaround 2025-11-26T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/605790a59e1e7555/enveric-biosciences-secures-fourth-patent-for-non-hallucinogenic-neuroplastogenic-drug-candidates 2025-11-26T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/d144278e1c9e4696/mount-sinai-researchers-develop-novel-mrna-therapy-to-combat-antibiotic-resistant-bacterial-infections 2025-11-26T17:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/40a795ee0d53f60e/scisparc-acquires-musetm-endoscopy-patents-to-target-3-billion-gerd-device-market 2025-11-26T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/9913899b9a199af9/xoma-royalty-completes-2-035-per-share-acquisition-of-mural-oncology 2025-11-26T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/f601521bbd0de26c/tangram-therapeutics-advances-novel-rnai-therapy-tgm-312-to-clinical-trials-for-mash-treatment 2025-11-26T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/0c28433cd2abc655/lighthouse-pharmaceuticals-secures-49-2m-nih-grant-for-novel-alzheimer-s-treatment-targeting-bacterial-driver 2025-11-26T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/1c6f3b783727aeba/fda-approves-novartis-gene-therapy-itvisma-for-spinal-muscular-atrophy-in-older-patients 2025-11-26T17:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/2327451409ee2dd5/clairity-myriad-genetics-and-magview-launch-first-integrated-ai-genetic-risk-platform-for-breast-cancer-screening 2025-11-26T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/bfe62fc35d850b16/real-world-atopic-dermatitis-patients-often-excluded-from-clinical-trials-study-reveals-safety-differences 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4868e0bb92517630/four-gene-signature-predicts-oxaliplatin-response-in-colorectal-cancer 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c69f19757edc616e/zymfentra-shows-consistent-efficacy-across-crohn-s-disease-locations-in-post-hoc-analysis-of-liberty-cd-study 2025-11-26T13:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/197587bba4929922/fda-launches-public-input-process-for-bsufa-iv-reauthorization-to-shape-biosimilar-regulatory-framework-through-2032 2025-11-26T09:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/557f3510f2173f9e/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma 2025-11-26T09:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/bffd2910c7b38801/samsung-biologics-reaches-400-global-manufacturing-approvals-reinforcing-cdmo-leadership 2025-11-26T09:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/f7092836a70253da/glenmark-launches-world-s-first-nebulized-triple-therapy-for-copd-treatment 2025-11-26T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/31dcf712a3cc17c0/galux-secures-29-million-series-b-to-advance-ai-driven-protein-design-platform 2025-11-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8e4d349754efbed/abbott-initiates-voluntary-correction-for-3-million-freestyle-libre-3-glucose-sensors-following-false-low-reading-reports 2025-11-26T05:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/60fe3d90607a0ef8/long-acting-donepezil-depot-injection-shows-promise-for-canine-cognitive-dysfunction-treatment 2025-11-26T05:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/aac2b73420b167f5/chugai-pharmaceutical-and-biomy-partner-to-develop-ai-powered-cancer-pathology-diagnostic-support-programs 2025-11-26T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/6418ddcfb6598f66/fda-extends-review-timeline-for-ascendis-pharma-s-achondroplasia-treatment-to-february-2026 2025-11-26T01:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/872b8e315fadc98a/chugai-s-port-delivery-system-with-ranibizumab-shows-promise-in-japanese-phase-i-ii-trial-for-retinal-diseases 2025-11-26T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/367d01a5f329629d/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns 2025-11-26T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/b124908f03880d6f/fda-grants-first-accelerated-approval-for-novel-iga-nephropathy-treatment-voyxact 2025-11-26T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/676aee21928ed75f/real-world-study-reveals-higher-than-expected-atrial-fibrillation-risk-with-mavacamten-in-hypertrophic-cardiomyopathy-patients 2025-11-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/91b18fda2bf8b8e4/novel-intravaginal-mrna-platform-delivers-enhanced-hiv-protection-through-localized-antibody-production 2025-11-25T21:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/4b399ea06c9b7abe/canada-s-1-5-billion-rare-disease-strategy-shows-early-success-with-nine-life-saving-treatments 2025-11-25T21:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/6fccea22b6816f26/novartis-restructures-swiss-operations-with-550-job-cuts-while-investing-80m-in-rna-therapy-production 2025-11-25T21:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/bd5dd8e1a850ad1a/gilead-acquires-sprint-bioscience-s-trex1-cancer-program-in-414-million-deal 2025-11-25T21:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/18b7e4d01ab702e6/lixte-biotechnology-acquires-liora-technologies-light-proton-therapy-system-for-cancer-treatment 2025-11-25T21:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/df75de3cd487b5b5/apatinib-plus-chemotherapy-extends-progression-free-survival-in-advanced-osteosarcoma-phase-ii-trial 2025-11-25T21:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/af28ddd5830c882f/ceribell-receives-fda-clearance-for-ai-powered-seizure-detection-in-neonates 2025-11-25T21:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/477658d1637048e1/zanidatamab-demonstrates-durable-responses-in-her2-positive-biliary-tract-cancer-earns-fda-accelerated-approval 2025-11-25T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/263f135fe5e9cbc6/new-market-analysis-reveals-global-monkeypox-clinical-trial-landscape-and-strategic-investment-opportunities 2025-11-25T21:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/eb91ca9715bad086/xenon-pharmaceuticals-to-present-long-term-azetukalner-data-at-aes-2025-highlighting-extended-seizure-freedom 2025-11-25T17:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/f5b7ba6a4058f5ff/sarepta-receives-fda-approval-for-enhanced-elevidys-gene-therapy-trial-in-non-ambulatory-duchenne-patients 2025-11-25T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/1db98bff546bb6c9/adalyon-appoints-former-novo-nordisk-director-as-ceo-to-advance-ai-powered-speech-biomarkers-for-clinical-trials 2025-11-25T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/51e92a3358baf6c9/innova-therapeutics-acquires-enci-therapeutics-to-advance-first-in-class-sfrp2-targeting-cancer-antibody 2025-11-25T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/de628705a71f2cff/who-approves-international-name-for-os-therapies-osteosarcoma-immunotherapy-ahead-of-regulatory-submissions 2025-11-25T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/5421672c74fb82f9/novo-nordisk-s-amycretin-shows-promising-phase-2-results-in-type-2-diabetes-advances-to-phase-3-trials 2025-11-25T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/2c9e31685c22f75f/caring-cross-partners-with-amrita-research-center-to-develop-affordable-car-t-and-gene-therapies-for-underserved-indian-populations 2025-11-25T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/9424ca996db58d34/tyrosine-kinase-inhibitors-and-gene-therapies-show-promise-for-wet-amd-treatment 2025-11-25T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/08a7936c2df09a3d/fda-expands-max-3tm-syringeless-mri-injector-for-use-with-vueway-r-imaging-bulk-package 2025-11-25T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/7288a378e4b7956d/precisionlife-and-ovation-partner-to-develop-precision-medicine-test-for-glp-1-drug-reimbursement 2025-11-25T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/25d2b9eb94dc0082/kelun-s-trop2-targeted-adc-shows-promise-in-first-line-lung-cancer-trial 2025-11-25T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/fe2826243a5e10da/pasithea-therapeutics-receives-1-million-als-association-grant-to-advance-pas-004-mek-inhibitor-in-phase-1-als-trial 2025-11-25T13:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/e5039822e034d12d/nice-recommends-aucatzyl-car-t-therapy-for-adult-relapsed-refractory-b-cell-all-in-england-and-wales 2025-11-25T13:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/d9c19ad9a1a515a5/active-biotech-secures-us-patent-for-tasquinimod-formulation-extending-market-exclusivity-to-2042 2025-11-25T13:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/a625501954117dce/biomed-x-and-abbvie-launch-neuroscience-collaboration-to-target-anhedonia-mechanisms 2025-11-25T09:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/2744fcfdebddb596/ai-powered-launch-intelligence-transforms-pharmaceutical-market-entry-strategy 2025-11-25T07:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/515327cafced23d6/european-commission-approves-dupixent-as-first-line-targeted-therapy-for-chronic-spontaneous-urticaria 2025-11-25T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/25227972c2a0aff3/ascentage-pharma-s-olverembatinib-shows-23-1-response-rate-in-rare-gist-subtype-with-novel-lipid-metabolism-mechanism 2025-11-25T05:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/9b238ade2a0f8d66/verrica-pharmaceuticals-secures-50-million-financing-to-advance-dermatology-pipeline-and-eliminate-debt 2025-11-25T05:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/f10547ade150a214/otsuka-submits-fda-application-for-first-in-class-adhd-drug-centanafadine 2025-11-25T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/ad40058687c80674/nhs-approves-breakthrough-car-t-therapy-obe-cel-for-aggressive-leukemia-with-77-remission-rate 2025-11-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/f83c63aeb700e776/glp-1-discontinuation-before-pregnancy-linked-to-increased-weight-gain-and-complications 2025-11-25T01:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/22b977fcc2e4c9e3/overweight-multiple-myeloma-patients-show-worse-outcomes-with-anti-bcma-car-t-therapy-in-u-shaped-bmi-pattern 2025-11-25T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/9e6b7b71c0f96a79/calcium-activated-switch-enhances-antibody-drug-conjugate-delivery-and-potency-in-cancer-treatment 2025-11-25T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/3f19ebe8411d230e/praxis-precision-medicines-to-showcase-epilepsy-pipeline-at-aes-2025-with-full-radiant-study-results 2025-11-25T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/cb7d00512d8a35dc/artera-s-ai-model-shows-promise-for-personalizing-breast-cancer-treatment-decisions 2025-11-25T01:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/f4965af8a77d188c/bristol-myers-squibb-receives-european-commission-approval-for-breyanzi-in-relapsed-refractory-mantle-cell-lymphoma 2025-11-25T01:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/3438ad1cacec0736/fda-approves-first-intrathecal-gene-therapy-for-spinal-muscular-atrophy-across-all-ages 2025-11-25T01:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/7f829fdf364dcdd8/aidoc-achieves-fda-clearance-for-healthcare-s-first-comprehensive-foundation-model-ai-triage-solution 2025-11-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6dfb02b01a210b94/thermo-fisher-scientific-opens-advanced-therapies-collaboration-center-in-philadelphia-to-accelerate-cell-and-gene-therapy-development 2025-11-24T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/02e7c40584c17e8e/enquyst-technologies-achieves-breakthrough-in-monoclonal-antibody-manufacturing-with-chromatography-free-purification-platform 2025-11-24T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/8064de7c695b9a9c/kelonia-s-in-vivo-car-t-therapy-shows-promising-early-results-in-multiple-myeloma-patients 2025-11-24T21:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/e026ec631ccddbb0/ucla-receives-6-7-million-grant-to-expand-groundbreaking-kidney-transplant-trial-that-eliminates-immunosuppressive-drugs 2025-11-24T21:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/f6185db119a5255b/adaptive-biotechnologies-clonoseq-mrd-test-featured-in-record-89-abstracts-at-ash-2025 2025-11-24T17:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/97ff8c857f823e21/day-one-reports-three-year-ojemda-data-shows-sustained-treatment-free-periods-in-pediatric-brain-cancer 2025-11-24T17:41:13+00:00 hourly 0.9 https://trial.medpath.com/news/c60acca2f56338f0/capricor-therapeutics-advances-exosome-drug-delivery-with-scalable-manufacturing-framework 2025-11-24T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/6d3f105926024ecb/dana-farber-presents-breakthrough-findings-in-blood-cancer-treatment-at-ash-2025 2025-11-24T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/610410621bf2081e/menarini-group-to-present-new-elzonris-data-at-ash-2025-including-promising-triplet-therapy-results-for-bpdcn 2025-11-24T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/7e6a8125028cd6de/harmony-biosciences-reports-positive-bioequivalence-results-for-pitolisant-gr-formulation-plans-2026-nda-submission 2025-11-24T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/6f7686fea3066a0b/invivyd-selects-vby329-as-potential-best-in-class-rsv-antibody-for-pediatric-prevention 2025-11-24T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/2b07c42f1e112f7c/adia-nutrition-submits-patent-pending-autism-protocol-for-irb-review-advancing-stem-cell-therapy-study 2025-11-24T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/d4bda1a95e77b723/vertero-therapeutics-launches-phase-1-trial-of-vt-5006-first-in-class-gut-selective-therapy-for-parkinson-s-disease 2025-11-24T17:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/1474bc899dd52dd0/amorphical-enrolls-first-patient-in-phase-2-trial-testing-novel-nano-amorphous-mineral-therapy-for-stage-iv-pancreatic-cancer 2025-11-24T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/5fae30237d9144b4/thiogenesis-therapeutics-plans-phase-3-trial-for-next-generation-cystinosis-treatment-tti-0102 2025-11-24T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/78dffa27aa118cb5/jyong-biotech-signs-letter-of-intent-for-mcs-2-licensing-in-south-korea 2025-11-24T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/b187c559656ba91b/can-fite-seeks-veterinary-partnerships-for-cancer-drug-namodenoson-at-biofit-2025 2025-11-24T17:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/47a6b292c47ce4c8/heidelberg-pharma-appoints-dr-dongzhou-jeffery-liu-as-new-ceo-amid-leadership-transition 2025-11-24T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/0bdb9dddfb6318cc/biogen-partners-with-dayra-therapeutics-in-50-million-deal-to-develop-oral-macrocyclic-peptides-for-immunological-conditions 2025-11-24T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/7f1745bf356f3ebf/oral-semaglutide-fails-to-slow-alzheimer-s-disease-progression-in-phase-3-trials 2025-11-24T17:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/79fe52dd7c77bfe6/in-vivo-car-t-therapies-drive-6-1-billion-in-biotech-acquisitions-as-investors-shift-from-traditional-cell-therapy-approaches 2025-11-24T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/fe431f418515fbce/merck-s-cladribine-capsules-receive-fda-fast-track-designation-for-rare-neuromuscular-disorder 2025-11-24T17:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/4bb137e342802386/ocular-therapeutix-initiates-helios-3-phase-3-trial-for-axpaxli-in-diabetic-retinopathy 2025-11-24T17:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/9f19a89cfb9b9e19/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-3-essential-thrombocythemia-trial 2025-11-24T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/7f0ecf88bf7dd3a2/johnson-johnson-s-posdinemab-fails-phase-2b-trial-dealing-blow-to-tau-targeting-alzheimer-s-therapies 2025-11-24T17:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/5aa67ec0e7e8e633/circular-genomics-unveils-blood-based-circular-rna-biomarkers-for-early-alzheimer-s-disease-detection 2025-11-24T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/6460b4db40c9d97d/versant-ventures-launches-dayra-therapeutics-with-70m-funding-and-biogen-partnership-for-oral-macrocyclic-peptides 2025-11-24T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/f223963ce85aa503/neurosense-receives-fda-clearance-for-pivotal-phase-3-trial-of-primec-in-als 2025-11-24T17:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/054d2b4a6a10698c/tumor-associated-macrophages-drive-gastric-cancer-progression-through-immune-evasion-and-therapeutic-resistance 2025-11-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0106a41107b1ea3a/century-old-diabetes-drug-metformin-reduces-insulin-requirements-in-type-1-diabetes-patients 2025-11-24T13:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/9dc0283ba83374f7/mrna-technology-shows-promise-for-preventing-muscle-damage-from-snakebites 2025-11-24T13:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/7a97886fc6ad8e2b/vaximm-secures-potential-835m-deal-with-bcm-europe-for-oral-cancer-immunotherapy-platform-vxm01 2025-11-24T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/bf2b2122293f3dac/genenta-science-reports-sustained-survival-benefits-in-glioblastoma-trial-with-temferon-cell-therapy 2025-11-24T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/2cfb1cf87f36c3ce/pin-therapeutics-begins-first-in-human-trial-of-ck1a-degrader-pin-5018-for-rare-adenoid-cystic-carcinoma 2025-11-24T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/59be93912158f638/ananda-pharma-exits-public-markets-and-nhs-epilepsy-trial-to-focus-on-pain-treatment-pipeline 2025-11-24T13:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/79eadb42a5dac780/abbott-laboratories-to-acquire-exact-sciences-for-21-billion-in-major-cancer-diagnostics-consolidation 2025-11-24T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/8f589c9c399e58e2/sequana-medical-achieves-first-u-s-commercial-implantation-of-alfapump-r-system-at-mount-sinai-hospital 2025-11-24T13:22:25+00:00 hourly 0.9 https://trial.medpath.com/news/9a17c9f32fac47b4/fda-cleared-ai-platform-somnum-reduces-sleep-clinical-trial-timelines-by-50 2025-11-24T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/fac0a0946bf8043a/biocortex-partners-with-cd-biopharma-to-accelerate-precision-immunotherapy-development-using-ai-driven-platform 2025-11-24T13:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/5d2fb11e32d7ebe8/dexamethasone-shows-promise-against-therapy-resistant-breast-cancer-metastases-in-preclinical-studies 2025-11-24T13:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/ebf9d615fb42064e/samsung-biologics-completes-strategic-spinoff-to-enhance-biosimilar-and-novel-drug-development 2025-11-24T09:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/e2c42b7e2ce28cf7/austrian-multicenter-study-demonstrates-hifu-as-effective-organ-preserving-treatment-for-early-prostate-cancer 2025-11-24T09:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/8ac782dde9562466/fda-regulatory-reversals-disrupt-drug-development-timelines-for-uniqure-biohaven-and-capricor 2025-11-24T09:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/92540c9225f16407/china-s-biotech-sector-emerges-as-key-player-as-big-pharma-faces-300-billion-patent-cliff-through-2030 2025-11-24T08:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/eaf5649ff4ad7959/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-across-multiple-development-phases 2025-11-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a7d07b83646a6d1/world-first-gene-therapy-shows-remarkable-success-in-three-year-old-with-hunter-syndrome 2025-11-24T05:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/51cc96c254b45224/harbour-biomed-expands-astrazeneca-partnership-for-next-generation-oncology-therapeutics 2025-11-24T05:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/f411db2b668cf995/geneditbio-and-toolgen-form-strategic-alliance-to-advance-crispr-based-cardiovascular-gene-therapy 2025-11-24T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/38e2b3432225f4bc/hpv-vaccination-shows-dramatic-80-reduction-in-cervical-cancer-risk-when-given-before-age-16 2025-11-24T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/084e9fe998f4d565/rakovina-therapeutics-presents-ai-discovered-cns-penetrant-atr-mtor-dual-inhibitors-at-neuro-oncology-meeting 2025-11-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/961f8f7f8003df72/bayer-s-asundexian-shows-promise-in-phase-iii-stroke-prevention-trial-after-2023-setback 2025-11-23T21:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/acacf264e81bf124/black-cumin-seed-shows-promise-for-cholesterol-management-and-fat-cell-inhibition-in-clinical-trial 2025-11-23T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/c4857c292d50487a/regulatory-t-cell-therapies-advance-through-clinical-development-with-enhanced-monitoring-technologies 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/58f62d1646ddc1b7/novel-bacteriophage-yz2-shows-promise-against-carbapenem-resistant-acinetobacter-baumannii-in-combination-therapy 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/71dbc0c8de9ababe/innocan-pharma-s-cbd-delivery-platform-achieves-28-day-sustained-release-in-regulatory-study 2025-11-23T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/e809e02629e12e1c/trikafta-shows-sustained-anti-inflammatory-effects-in-cystic-fibrosis-patients-through-2-5-years 2025-11-23T09:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/0321033df02cf7e1/gho-capital-partners-acquires-ai-powered-r-d-platform-scientist-com-to-accelerate-pharmaceutical-research-efficiency 2025-11-23T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/55682160720c5314/erdafitinib-shows-promising-early-efficacy-and-manageable-safety-profile-in-fgfr-tacc-fusion-positive-glioma 2025-11-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/d50fb8a1c018425c/shilpa-medicare-receives-eight-fda-observations-following-ten-day-inspection-at-jadcherla-manufacturing-facility 2025-11-23T05:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/d4c3b3d77276a5d2/fda-s-new-drug-chief-pazdur-challenges-commissioner-s-expedited-approval-plans 2025-11-23T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/29a0f38cebab0b57/first-in-human-trial-shows-safety-of-intraventricular-her2-car-t-therapy-for-brain-metastases-in-breast-cancer 2025-11-23T01:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/9cab2917fef7035d/lutetium-lu-177-dotatate-demonstrates-significant-efficacy-in-advanced-intracranial-meningioma-phase-2-trial 2025-11-23T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/ca5651fcd9a89cfd/scientists-identify-rna-molecule-that-may-reverse-als-nerve-damage-in-preclinical-studies 2025-11-23T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/2c48d2e182c29e64/oral-arginine-shows-promise-as-cost-effective-alzheimer-s-treatment-in-preclinical-studies 2025-11-22T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/5f4fb63caba20998/ajinomoto-partners-with-forge-biologics-to-double-gene-therapy-manufacturing-productivity 2025-11-22T21:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/7e1a84188e252c25/cassandra-phase-3-trial-shows-paxg-superior-to-mfolfirinox-in-preoperative-pancreatic-cancer-treatment 2025-11-22T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/af8de33ab7dfc0b1/phase-1-regoma-2-trial-establishes-safe-dosing-for-regorafenib-combination-in-mgmt-methylated-glioblastoma 2025-11-22T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/a37713e65b2d05af/uskudar-university-partners-with-sartorius-to-advance-gene-therapy-and-cell-based-treatment-manufacturing-in-turkey 2025-11-22T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/2ed799ae7eb83180/combicor-vax-phase-ii-trial-combines-dendritic-cell-vaccine-with-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2025-11-22T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/f1ac9944e51a4a4a/osr-holdings-subsidiary-vaximm-secures-835m-licensing-deal-for-oral-cancer-immunotherapy-vxm01 2025-11-22T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/d617f1abc5dfd485/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-cardiovascular-disease 2025-11-22T05:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/13a6dda8ecc55b62/real-world-study-reveals-treatment-gap-in-idh-mutant-glioma-supporting-need-for-early-intervention 2025-11-22T05:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/c8ffd319d5324f70/mirdametinib-achieves-87-response-rate-in-pediatric-low-grade-glioma-phase-1-2-trial 2025-11-22T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/8bd0154af963c45d/long-term-mirdametinib-data-shows-improved-response-rates-and-deeper-tumor-shrinkage-in-nf1-associated-plexiform-neurofibromas 2025-11-22T05:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/8e2f0d0ce9907284/immune-checkpoint-inhibitors-show-promise-for-triple-negative-breast-cancer-despite-increased-toxicity-risks 2025-11-22T05:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/f1651192ec1252c4/praxis-precision-medicines-advances-multiple-neurological-programs-following-essential-tremor-success 2025-11-22T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/1ad606aacff2d5a9/aston-university-and-comvita-file-patent-for-enhanced-manuka-honey-formulation-against-drug-resistant-bacteria 2025-11-22T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/773df3bde105fc00/uk-launches-first-clinical-trial-of-puberty-blockers-following-government-ban 2025-11-22T05:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/787ef6e2f9bdd290/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-countermeasure-in-collaboration-with-canadian-defense-agency 2025-11-21T21:43:28+00:00 hourly 0.9 https://trial.medpath.com/news/bce0987daac7cef4/fda-investigates-fatal-adverse-event-linked-to-takeda-s-adzynma-enzyme-replacement-therapy 2025-11-21T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/ebc72eb6fa4d3a5f/guselkumab-shows-superior-treatment-persistence-over-il-17a-inhibitors-in-psoriatic-arthritis-study 2025-11-21T21:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/b325db29195bc2ed/astrazeneca-commits-2-billion-to-expand-maryland-manufacturing-operations-doubling-biologics-capacity 2025-11-21T21:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/62852b97692ec9d1/gsk-and-anaptysbio-file-dueling-lawsuits-over-jemperli-royalty-agreement-as-cancer-drug-nears-blockbuster-status 2025-11-21T21:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/cbeb5bac9f389048/university-of-cincinnati-leads-multicenter-trial-testing-extended-tranexamic-acid-for-acl-surgery-recovery 2025-11-21T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/428edbb7a3857b74/u-s-cell-and-gene-therapy-cdmo-market-set-for-explosive-growth-projected-to-reach-10-34-billion-by-2033 2025-11-21T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/670d920c0300fd98/five-year-juliet-trial-data-confirms-tisagenlecleucel-as-curative-car-t-therapy-for-relapsed-refractory-large-b-cell-lymphoma 2025-11-21T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/1dff7f70211945d3/polaryx-therapeutics-secures-nasdaq-listing-ahead-of-phase-2-trial-for-rare-lysosomal-storage-disorders 2025-11-21T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/93f894d951cdc71e/northwest-biotherapeutics-begins-construction-of-advanced-grade-c-manufacturing-suite-to-scale-dcvax-production 2025-11-21T17:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/5c5d76ccded8019a/sorcero-raises-42-5m-series-b-to-scale-ai-platform-for-life-sciences-evidence-generation 2025-11-21T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/d061db2321989bd1/fda-lifts-clinical-hold-on-blue-lake-s-pediatric-rsv-vaccine-trial-allowing-enrollment-of-rsv-negative-toddlers 2025-11-21T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/79197f91cda1c64f/nice-approves-alnylam-s-vutrisiran-for-nhs-use-in-rare-heart-condition-attr-cm 2025-11-21T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/d3543deadea72320/waltz-health-launches-industry-first-direct-to-employer-model-for-obesity-medications 2025-11-21T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/0ff2b1637250ca1d/evofem-s-phexx-advances-toward-uae-approval-as-first-hormone-free-contraceptive-gel 2025-11-21T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/935ec2c8d42ee079/contineum-therapeutics-pipe-307-fails-phase-2-multiple-sclerosis-trial 2025-11-21T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/ba2c150f4bd5a7cb/bioatla-secures-22-5-million-flexible-financing-to-support-operations-while-pursuing-strategic-partnership 2025-11-21T13:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/57c297b6476ecf3e/crossbridge-bio-secures-15-million-cprit-grant-to-advance-novel-dual-payload-adc-cbb-120-targeting-trop-2 2025-11-21T13:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/5ef416f003f34d8c/meril-s-myval-transcatheter-heart-valve-shows-comparable-one-year-outcomes-to-leading-competitors-in-landmark-trial 2025-11-21T13:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/7a54f95438fa85b5/car-t-cell-therapy-shows-70-reduction-in-atherosclerotic-plaque-in-preclinical-study 2025-11-21T13:53:45+00:00 hourly 0.9 https://trial.medpath.com/news/ef39b02f0ce99217/dicot-pharma-s-lib-01-shows-sustained-erectile-dysfunction-treatment-effects-in-phase-2a-trial 2025-11-21T13:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/eae1273a61f07326/cancer-cell-derived-il-1b-identified-as-key-mechanism-reversing-chemo-immunotherapy-resistance-in-nsclc 2025-11-21T13:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/d19bc49c2f433c4d/gsk-subsidiary-tesaro-files-lawsuit-against-anaptysbio-over-jemperli-license-breach 2025-11-21T13:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/e1028bdeb0768eff/curatis-secures-chf-1-2-million-to-accelerate-late-stage-corticorelin-development 2025-11-21T13:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/0653b6934463d6fa/pacbio-gains-china-regulatory-approval-for-clinical-grade-long-read-sequencing-system 2025-11-21T13:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/bd139a2e8c6ab0a0/revir-therapeutics-secures-4-6m-cirm-grant-for-dual-target-huntington-s-disease-therapy 2025-11-21T09:57:41+00:00 hourly 0.9 https://trial.medpath.com/news/9fc432c33c6bc14a/onco-innovations-advances-pnkp-inhibitor-manufacturing-scale-up-with-dalton-pharma-for-phase-1-clinical-trials 2025-11-21T09:55:34+00:00 hourly 0.9 https://trial.medpath.com/news/9b28eb4086fa3872/supreme-court-declines-patent-review-case-strengthening-ptab-authority-over-expired-patents 2025-11-21T01:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/1410b8c83e285b99/actimed-therapeutics-partners-with-mankind-pharma-for-cancer-cachexia-treatment-development-in-south-asia 2025-11-21T01:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/c3ffe0fa1c47b432/rare-pole-gene-mutation-predicts-strong-immunotherapy-response-in-colorectal-cancer 2025-11-21T01:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/44526b5741ca1f4b/innocan-pharma-s-liposomal-cbd-platform-shows-28-day-sustained-release-in-preclinical-study 2025-11-21T01:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/fe60b7804f7daec6/os-therapies-plans-spinoff-of-animal-health-subsidiary-to-advance-canine-osteosarcoma-treatment 2025-11-21T01:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/b6ea3bf96398c995/moderna-secures-1-5-billion-loan-to-advance-pipeline-beyond-covid-19-vaccines 2025-11-21T01:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/f6d7007f8765d7f4/inhibikase-therapeutics-advances-ikt-001-to-global-phase-3-study-for-pulmonary-arterial-hypertension 2025-11-21T01:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/406b5ffe1f37294b/fda-approves-multiple-new-cancer-therapies-including-bayer-s-hyrnuo-for-nsclc-and-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-11-21T01:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/602b60e008d0cd27/neurocrine-review-reveals-key-differences-between-fda-approved-tardive-dyskinesia-treatments 2025-11-21T01:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/d812f39f129a4c14/aurigene-s-malt1-inhibitor-aur112-shows-63-6-response-rate-in-phase-1-lymphoma-trial 2025-11-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc75d6d130bab089/samsung-bioepis-explores-organon-acquisition-to-shift-from-partner-based-to-direct-sales-model 2025-11-20T22:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/a75d0d793d9b5b50/european-medicines-agency-recommends-approval-for-two-boehringer-ingelheim-avian-flu-vaccines 2025-11-20T21:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/d9dfde932b76add3/syncromune-s-sync-t-therapy-shows-bone-metastases-resolution-in-phase-1-prostate-cancer-trial 2025-11-20T21:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/6930fbfe9e405d00/mink-therapeutics-reports-preclinical-success-for-mink-215-car-inkt-therapy-in-treatment-resistant-solid-tumors 2025-11-20T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/35ab00ec7b397f5c/fibrobiologics-secures-regulatory-approval-for-phase-1-2-trial-of-cywc628-in-diabetic-foot-ulcers 2025-11-20T21:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/370af22a8ee75c09/polymodels-hub-raises-eur7-9m-series-a-to-transform-biopharma-process-development-with-ai-driven-platform 2025-11-20T21:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/968edd45692cfcb4/mauna-kea-technologies-secures-nmpa-approval-for-next-generation-cellvizio-platform-in-china 2025-11-20T21:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/ce66891450a4aa0d/can-fite-s-cf602-receives-patent-protection-in-brazil-for-novel-erectile-dysfunction-treatment 2025-11-20T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/bdd443cb0fa40882/pepromene-bio-s-baffr-car-t-therapy-shows-promising-results-in-relapsed-b-cell-cancers 2025-11-20T17:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/d4f686d89bda3894/vivac-pharma-appoints-keren-leshem-as-ceo-to-advance-rna-lipid-nanoparticle-cancer-immunotherapy-platform 2025-11-20T17:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/d5fb9ab0c02d4a12/minovia-s-mitochondrial-therapy-shows-promise-in-myelodysplastic-syndrome-phase-1b-trial 2025-11-20T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/89c37da659c9a238/hitgen-secures-gates-foundation-funding-for-drug-discovery-targeting-tuberculosis-malaria-and-non-hormonal-contraception 2025-11-20T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/7263146b5f482ba3/merck-kgaa-partners-with-valo-health-in-3-billion-ai-driven-parkinson-s-drug-discovery-deal 2025-11-20T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/b8c12caa4ee8f06f/qsimulate-raises-11m-in-seed-funding-launches-quelo-v2-3-quantum-platform-for-peptide-drug-discovery 2025-11-20T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/8e1ee74d8834f6e0/abbott-to-acquire-exact-sciences-for-21-billion-expanding-cancer-diagnostics-portfolio 2025-11-20T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/072ecad4fd9d3623/briacell-partners-with-receptor-ai-to-develop-ai-driven-cancer-kinase-inhibitors 2025-11-20T17:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/0c4d16d792bd5eab/oncotelic-s-pipeline-receives-1-7-billion-valuation-as-ot-101-advances-to-phase-3-trials 2025-11-20T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/b076fcaffd5a9498/fda-approves-accord-biopharma-s-denosumab-biosimilars-osvyrti-and-jubereq-for-bone-disorders 2025-11-20T17:22:06+00:00 hourly 0.9 https://trial.medpath.com/news/90d2bcb247d78a8f/edgewise-therapeutics-strengthens-board-with-commercial-veteran-ahead-of-becker-muscular-dystrophy-launch 2025-11-20T17:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/14b46c85107ba52b/unige-scientists-develop-dual-target-car-t-cell-therapy-for-treatment-resistant-glioblastoma 2025-11-20T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/b0f0f408f6ed9ec9/apoptotic-extracellular-vesicles-emerge-as-novel-biomarkers-for-cancer-and-neurodegenerative-disease-diagnosis 2025-11-20T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93886342aebe41ce/moderna-unveils-three-year-growth-strategy-with-expanded-vaccine-portfolio-and-oncology-focus 2025-11-20T13:27:49+00:00 hourly 0.9 https://trial.medpath.com/news/ec7bd4dd8cfdcd74/novartis-raises-peak-sales-targets-for-cancer-drugs-kisqali-and-scemblix-forecasts-5-6-annual-growth-through-2030 2025-11-20T13:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/5ff4aae77e9d5ba5/imperial-college-spinout-biocentis-raises-19-million-to-advance-genome-engineered-insect-control-technology 2025-11-20T13:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/4f4b74451477fe21/quantum-si-advances-proteus-platform-development-with-breakthrough-controlled-cleavage-chemistry-for-protein-sequencing 2025-11-20T13:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/b5a761206bdb8f4f/ono-pharmaceutical-secures-approvals-for-braftovi-combination-therapy-in-braf-mutant-colorectal-cancer 2025-11-20T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/92bd1847ea742457/flagship-pioneering-companies-enter-first-gsk-collaboration-agreements-to-target-respiratory-and-liver-diseases 2025-11-20T13:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/4c5515e1d6c6a9f3/novartis-projects-5-6-annual-growth-through-2030-backed-by-multi-billion-dollar-drug-portfolio 2025-11-20T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/1730e74320120197/french-researchers-develop-novel-mrna-ultrasound-combination-therapy-for-pancreatic-cancer 2025-11-20T09:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/fb7c59097aa040ab/poolbeg-pharma-secures-european-patent-for-polb-001-targeting-severe-influenza-and-cancer-immunotherapy-side-effects 2025-11-20T09:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/ac668447d2cab6c7/nhs-positioned-as-global-innovation-testbed-as-uk-attracts-40-billion-in-technology-investment 2025-11-20T09:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/c1b8a18a40893f6b/dexcom-launches-extended-15-day-g7-cgm-system-in-us-and-expands-g7-availability-in-kuwait 2025-11-20T08:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9779f4d30ed1866/arch-biopartners-secures-600000-cad-to-advance-kidney-disease-drug-development 2025-11-20T05:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/af75be9a0ac714b6/impact-biotech-reports-73-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-utuc 2025-11-20T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/5791cdf2e7d76d63/surenano-science-enters-letter-of-intent-to-acquire-glp-1-drug-developer-glucapharm 2025-11-20T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/620cbef348da63f0/checkmate-648-and-keynote-590-establish-chemo-immunotherapy-as-first-line-standard-for-advanced-esophageal-squamous-cell-carcinoma 2025-11-20T01:24:20+00:00 hourly 0.9 https://trial.medpath.com/news/d813d14368fa70e4/pfizer-s-mrna-flu-vaccine-shows-34-5-superior-efficacy-in-phase-3-trial 2025-11-20T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/a86ded46bc870bbd/johns-hopkins-researchers-patent-enhanced-mebendazole-formulation-for-cancer-treatment 2025-11-20T01:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/93054602aad0ff95/fda-approves-abbvie-and-genmab-s-epkinly-for-relapsed-or-refractory-follicular-lymphoma 2025-11-20T01:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/cc93dc846744232b/fda-grants-full-approval-to-amgen-s-imdelltra-for-extensive-stage-small-cell-lung-cancer 2025-11-20T01:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/94fa77cdeee66c53/insphero-acquires-doppl-sa-and-sun-bioscience-gri3d-technology-to-create-comprehensive-3d-cell-model-platform 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/712eab80f4f71b23/ensysce-biosciences-advances-pf614-phase-3-trial-with-fda-manufacturing-approval-and-extended-patent-protection 2025-11-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e08fb188f7051f45/precise-bio-achieves-world-s-first-3d-bioprinted-corneal-implant-in-human-patient 2025-11-19T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/098d759496462902/dialectic-therapeutics-initiates-phase-1b-2-trial-of-dt2216-in-platinum-resistant-ovarian-cancer 2025-11-19T21:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/546241f43140f273/avicanna-s-novel-pwdrx-platform-shows-74-higher-bioavailability-for-cannabinoid-delivery-in-preclinical-studies 2025-11-19T21:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/7262c1dbf724eb74/kaimrc-and-flagship-pioneering-form-70m-partnership-for-genetic-disease-clinical-trials-in-saudi-arabia 2025-11-19T21:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/cf194c07f518cf76/aperture-therapeutics-advances-cd33-targeting-antisense-oligonucleotide-aprtx-001-for-neurodegenerative-diseases 2025-11-19T21:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/3e506cbf2cb4ed8a/hrv-pharma-and-metrochem-form-strategic-cdmo-partnership-for-high-value-api-development 2025-11-19T21:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/0ad088911e0aac2b/skin-permeable-polymer-delivers-insulin-through-topical-cream-offering-needle-free-diabetes-treatment 2025-11-19T21:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/97ab8a4bd45af616/abbott-laboratories-acquires-exact-sciences-for-21-billion-to-expand-cancer-diagnostics-portfolio 2025-11-19T19:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/47750c30a9834669/new-analysis-reveals-909-immunology-deals-worth-billions-in-biopharma-partnerships-from-2016-2025 2025-11-19T17:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/5d840418ffd77c7b/scynexis-completes-brexafemme-nda-transfer-to-gsk-enabling-antifungal-drug-relaunch 2025-11-19T17:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/66d6d8473d071b37/rxcelerate-and-constructive-bio-form-strategic-partnership-to-develop-next-generation-biologics-using-programmable-biology-platform 2025-11-19T17:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/0d47596a8face2f8/moderna-completes-140-million-u-s-manufacturing-expansion-to-enable-full-domestic-mrna-production 2025-11-19T17:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/7474ee65847402c8/agios-mitapivat-shows-mixed-results-in-phase-3-sickle-cell-disease-trial 2025-11-19T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/0003550a000dcd80/respirerx-secures-1-5m-nih-grant-to-advance-novel-epilepsy-treatment-krm-ii-81-toward-clinical-trials 2025-11-19T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/e3cd452e6ba1da56/novel-gene-therapy-avgn7-2-shows-promising-safety-profile-in-preclinical-study-for-inclusion-body-myositis 2025-11-19T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/01a3a86d7a830bd3/distalmotion-secures-150m-series-g-to-expand-dexter-surgical-robot-in-u-s-ambulatory-surgery-centers 2025-11-19T17:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/0864d2707282b135/synthio-labs-raises-5-million-to-transform-life-sciences-customer-engagement-with-clinical-voice-ai 2025-11-19T17:26:44+00:00 hourly 0.9 https://trial.medpath.com/news/4e3d7f1a7c5fd296/c-light-technologies-wins-roche-ms-innovation-challenge-to-develop-eye-movement-biomarkers-for-multiple-sclerosis-progression 2025-11-19T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/e5a1cd3b02ec6f3b/kalivir-partners-with-roche-to-test-novel-oncolytic-immunotherapy-vet3-tgi-in-combination-with-tecentriq 2025-11-19T17:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/051126b12fe14d60/olema-pharmaceuticals-stock-falls-7-after-announcing-public-offering-to-fund-breast-cancer-pipeline 2025-11-19T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/d523261e50ff31ab/tempest-therapeutics-acquires-dual-car-t-programs-from-factor-bioscience-in-strategic-all-stock-transaction 2025-11-19T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/d9a41858a079d494/elicio-therapeutics-appoints-marc-wolfgang-as-cto-to-strengthen-commercial-readiness-for-kras-targeted-cancer-immunotherapy 2025-11-19T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/3f98cd853fd8b81c/fyr-bio-and-nuvox-therapeutics-secure-1-98m-nci-grant-to-advance-liquid-biopsy-technology-in-glioblastoma-trial 2025-11-19T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/b03c5156e04a3733/pfizer-partners-with-nona-biosciences-for-heavy-chain-only-antibody-discovery-platform 2025-11-19T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/6bf414167c2cd519/alzamend-neuro-completes-phase-ii-brain-imaging-study-of-novel-lithium-therapy-al001 2025-11-19T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/f83691377eff040e/onepot-ai-emerges-from-stealth-with-13m-to-accelerate-drug-synthesis-using-ai-powered-chemistry 2025-11-19T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/1119bc7537b66fb4/india-launches-indigenous-crispr-gene-therapy-birsa-101-for-sickle-cell-disease-targeting-tribal-communities 2025-11-19T17:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/1d8123f281265085/agios-mitapivat-shows-mixed-results-in-sickle-cell-disease-phase-3-trial 2025-11-19T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/68790de2d6566d6f/tara-002-achieves-100-clinical-success-rate-in-phase-2-trial-for-pediatric-lymphatic-malformations 2025-11-19T17:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/d1a8bb0db2bebc16/dupilumab-demonstrates-superior-2-year-drug-survival-in-atopic-dermatitis-treatment-landscape 2025-11-19T15:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/13b43004438d26da/fda-clears-dexcom-smart-basal-as-first-cgm-integrated-insulin-dosing-optimizer-for-type-2-diabetes 2025-11-19T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/58c105b067a023d5/profluent-secures-106m-to-advance-ai-driven-protein-design-platform 2025-11-19T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/94707f65fc2c4b66/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-atherosclerotic-cardiovascular-disease 2025-11-19T13:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/2c8460d52c8b6cfa/piramal-pharma-solutions-uk-adc-manufacturing-facility-receives-updated-mhra-gmp-certification 2025-11-19T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/6084d01a82ac337c/canon-medical-receives-fda-clearance-for-advanced-interventional-imaging-systems-with-ai-enhanced-technology 2025-11-19T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/31e887de960b9b15/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engagers-for-cancer-treatment 2025-11-19T09:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/cc0dd0c51705478c/breakthrough-in-remote-alzheimer-s-testing-finger-prick-blood-samples-enable-global-disease-detection 2025-11-19T09:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/28627ae29d3558f9/renalytix-s-kidneyintelx-dkd-test-shows-superior-ckd-risk-prediction-in-major-diabetes-care-study 2025-11-19T09:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/e9f400e27d016524/first-patient-dosed-with-iv-psilocin-in-groundbreaking-binge-eating-disorder-trial 2025-11-19T09:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/196bdbfe4eee7bd3/european-budget-impact-study-validates-economic-benefits-of-blue-light-cystoscopy-for-bladder-cancer-diagnosis 2025-11-19T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/8bc06b492e70312b/yoltech-therapeutics-receives-fda-clearance-for-first-pivotal-trial-of-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1 2025-11-19T05:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/bb089c0a6443a2d1/cognito-therapeutics-spectris-device-shows-promise-in-modulating-brain-resilience-pathways-in-alzheimer-s-disease 2025-11-19T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/05bede9fc66958cb/brain-biomarkers-predict-deep-brain-stimulation-success-in-treatment-resistant-depression 2025-11-19T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/b37f1420ea3dded2/lynk-pharmaceuticals-topical-jak-inhibitor-lnk01004-shows-promising-phase-ii-results-for-moderate-to-severe-atopic-dermatitis 2025-11-19T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/7678927479ec0fa4/familywell-health-secures-8m-series-a-to-expand-integrated-women-s-mental-health-platform 2025-11-19T01:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/e92f23d802410e03/vincere-biosciences-secures-5-million-mjff-grant-to-advance-first-in-class-parkinson-s-usp30-inhibitor-to-clinical-trials 2025-11-19T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/6ccbfb670e4b8739/vast-therapeutics-alx1-shows-promising-safety-profile-in-phase-1-trial-for-chronic-respiratory-diseases 2025-11-19T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/486ec73f8ed26c6c/nervgen-pharma-secures-10-million-funding-to-advance-first-in-class-spinal-cord-injury-therapy-nvg-291 2025-11-19T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/935fba57d5c86ad1/truth-dkd-trial-compares-tofogliflozin-and-metformin-for-diabetic-kidney-disease-treatment 2025-11-19T01:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/0bc59ec8dd337491/biocytics-achieves-fda-interact-meeting-milestone-for-point-of-care-cell-therapy-platform 2025-11-19T01:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/d742a8915eaf0c3b/onco-innovations-partners-with-kuano-to-apply-quantum-computing-to-pnkp-inhibitor-development 2025-11-19T01:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/3f3d35949b7f3731/nature-cell-to-establish-4m-stem-cell-manufacturing-facility-in-baltimore-creating-500-jobs 2025-11-19T01:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/c9e2096c0a192c72/three-year-izervay-data-shows-sustained-reduction-in-geographic-atrophy-lesion-growth 2025-11-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5505f965c91af8e6/alector-s-late-stage-frontotemporal-dementia-drug-fails-phase-iii-trial-company-cuts-workforce-by-49 2025-11-18T21:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/20e499373295444d/federal-circuit-invalidates-39-million-hair-loss-drug-patent-in-sandoz-victory 2025-11-18T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/654b4057eb605f3f/invenirex-secures-ps2m-to-commercialize-revolutionary-dna-nanotechnology-platform-for-ultra-early-disease-detection 2025-11-18T21:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/c21e9f823d71be6a/eve-bio-and-drugbank-partner-to-integrate-record-scale-pharmome-mapping-data-into-drug-discovery-platform 2025-11-18T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/9617d2be76f4b5f5/metformin-fails-to-delay-progression-in-low-risk-prostate-cancer-active-surveillance 2025-11-18T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/501415ed5ad29b30/arrowhead-pharmaceuticals-secures-first-fda-approval-with-redemplo-for-rare-genetic-disorder 2025-11-18T21:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/523cf291e2d84a6f/fda-approves-first-sirna-therapy-plozasiran-for-rare-metabolic-disorder-familial-chylomicronemia-syndrome 2025-11-18T21:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/55cf67a0cc1f4a3d/nice-approves-talquetamab-for-nhs-use-offering-new-hope-for-multiple-myeloma-patients 2025-11-18T21:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/1e14029b793692f5/oxford-and-gsk-launch-ps50-million-partnership-to-advance-cancer-prevention-and-inflammatory-disease-research 2025-11-18T21:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/9c108a530b2ff2dd/regeneron-seeks-to-strike-amgen-s-patent-counterclaims-in-aflibercept-biosimilar-litigation 2025-11-18T19:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/59554a95d2628eb5/arcera-life-sciences-launches-breakthrough-antibiotic-in-uae-to-combat-antimicrobial-resistance 2025-11-18T18:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/b7210aa5d8a66f8b/health-canada-approves-nilemdo-for-ldl-cholesterol-reduction-in-cardiovascular-disease-patients 2025-11-18T17:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/1e077c45e861379c/vyome-holdings-reports-positive-phase-2-results-for-vt-1953-in-malignant-fungating-wounds 2025-11-18T17:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/1b5e2daf3b01656e/clairity-secures-43m-series-b-to-commercialize-first-fda-authorized-ai-platform-for-breast-cancer-risk-prediction 2025-11-18T17:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/5f37d2b777406fb3/inmed-s-alzheimer-s-drug-candidate-inm-901-shows-favorable-bioavailability-in-large-animal-studies 2025-11-18T17:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/92c01fdc3c95c43d/singapore-researchers-develop-rna-therapy-targeting-undruggable-kras-cancer-gene 2025-11-18T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/69934aaefc8e0fd0/thermo-fisher-scientific-opens-east-coast-advanced-therapies-collaboration-center-to-accelerate-cell-and-gene-therapy-development 2025-11-18T17:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/16b7c9dd5d16ee6a/hermes-biosciences-secures-seed-funding-to-advance-extracellular-vesicle-isolation-technology-for-precision-medicine 2025-11-18T17:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/12ef460cec783282/zymeworks-pivots-to-royalty-driven-model-following-ziihera-s-late-stage-success-in-gastroesophageal-cancer 2025-11-18T17:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/6197c75326f18c92/brazilian-researchers-identify-amazon-scorpion-venom-peptide-with-promising-anti-breast-cancer-activity 2025-11-18T17:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/8d553440a34fe268/radiopharm-theranostics-receives-ethics-approval-for-first-in-human-trial-of-rad-402-in-advanced-prostate-cancer 2025-11-18T17:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/ced64b8355e1ff15/mabloc-and-instituto-butantan-partner-to-develop-first-in-class-monoclonal-antibody-therapy-for-yellow-fever 2025-11-18T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/71bcd501d0d4b252/federal-circuit-upholds-patent-invalidation-of-merck-s-oral-cladribine-ms-treatment-regimen 2025-11-18T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/e2e34a2f66de6806/hcw-biologics-initiates-first-in-human-trial-of-il-2-fusion-therapy-hcw9302-for-alopecia-areata 2025-11-18T17:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/c03dc58affd2c5f4/quanterix-validates-dual-blood-biomarker-test-for-comprehensive-multiple-sclerosis-monitoring 2025-11-18T17:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/ea226802c11ef5c2/csl-announces-1-5-billion-u-s-investment-to-expand-plasma-derived-therapy-manufacturing 2025-11-18T17:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/e0f43b90bdcd17e9/hepatitis-c-pricing-wars-of-2014-offer-blueprint-for-current-glp-1-obesity-drug-competition 2025-11-18T17:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/e3470ced4fa903f1/tivic-health-secures-barda-meeting-to-advance-entolimod-for-acute-radiation-syndrome 2025-11-18T17:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/494347a91310a523/kangpu-s-novel-cereblon-modulator-shows-50-response-rate-in-heavily-pre-treated-multiple-myeloma-patients 2025-11-18T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/b5764eecfeb1272f/vanda-s-tradipitant-reduces-glp-1-induced-vomiting-by-50-in-phase-2-trial 2025-11-18T17:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/a1d9cc8b02a55193/can-fite-reports-9-year-complete-response-in-advanced-liver-cancer-patient-as-phase-iii-trial-enrolls 2025-11-18T17:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/e28159dcca0e6213/bionet-s-vacpertagen-receives-positive-ema-opinion-as-first-standalone-pertussis-vaccine-in-eu 2025-11-18T17:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/e32493aaf9988d08/uk-launches-ps18-8-million-initiative-to-transform-nuclear-waste-into-precision-cancer-therapies 2025-11-18T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/56b48f6ca2e251ee/nanopath-receives-fda-breakthrough-device-designation-for-point-of-care-molecular-uti-diagnostic-platform 2025-11-18T17:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/4c04addf9fde3574/fda-approves-first-antithrombin-concentrate-for-pediatric-patients-with-hereditary-antithrombin-deficiency 2025-11-18T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/c67ee0b2387c2c91/cryotherapeutics-launches-icecap-trial-combining-cryotherapy-with-ai-powered-imaging-to-target-high-risk-coronary-plaques 2025-11-18T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/613dd3489250e343/advocate-health-launches-nation-s-largest-clinical-trial-network-to-democratize-access-to-breakthrough-treatments 2025-11-18T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/fbe4682403989a6a/fda-approves-first-bispecific-antibody-combination-for-relapsed-refractory-follicular-lymphoma 2025-11-18T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/9038350ed1a6aba4/mro-acquires-ai-driven-clinical-trial-recruitment-platform-clinetic-to-streamline-patient-enrollment 2025-11-18T17:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/d5dd760c6b7522a8/cellbyte-secures-2-75m-to-accelerate-drug-launch-timelines-with-ai-platform 2025-11-18T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/6beb6eb580992a26/health-canada-opens-consultation-on-decentralized-clinical-trials-guidance-as-global-regulatory-frameworks-converge 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f90a20f5c5e06ebc/multiple-sclerosis-patients-show-preserved-covid-19-vaccine-responses-despite-disease-modifying-therapies 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5d9d42995c67605/dual-pd-1-ctla-4-immunotherapy-shows-promise-in-ovarian-cancer-treatment 2025-11-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c200552b2d3456e0/european-commission-approves-world-s-first-liquid-formulation-of-iv-infliximab-promising-significant-cost-savings 2025-11-18T13:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/3acd7b6b52ae907d/emulate-and-fujifilm-launch-brain-chip-r1-to-overcome-blood-brain-barrier-challenges-in-cns-drug-development 2025-11-18T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/83cc6e24d2f5c135/avanzanite-secures-eur32m-series-a-to-scale-rare-disease-drug-access-across-europe 2025-11-18T13:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/66a06e06fa2b97a6/medicinova-strengthens-leadership-with-fda-veteran-dr-christopher-breder-as-clinical-and-regulatory-advisor 2025-11-18T13:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/4247f200e01de868/koru-medical-submits-fda-510-k-application-for-freedomedge-infusion-system-with-oncology-biologic-phesgo 2025-11-18T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/d69bc88907bf38f7/federal-circuit-overturns-39-million-jury-verdict-invalidates-allergan-hair-loss-patent-for-inadequate-written-description 2025-11-18T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff1ac50d9bf2c03a/ubivac-s-dpv-001-cancer-vaccine-shows-3x-response-rate-improvement-in-head-and-neck-cancer-trial 2025-11-18T09:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/431d99a64030d39d/gsk-and-fleming-initiative-launch-ps45m-ai-powered-research-program-to-combat-antimicrobial-resistance 2025-11-18T09:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/cb80595bdc36ceba/biomx-secures-3-0-million-private-placement-to-advance-bacteriophage-therapies-for-bacterial-infections 2025-11-18T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/e667fbf963b0297e/mainz-biomed-achieves-100-sensitivity-in-pancreatic-cancer-blood-test-feasibility-study 2025-11-18T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a622b1f9a9d68ea/sonoma-biotherapeutics-appoints-new-ceo-following-positive-treg-therapy-trial-results 2025-11-18T05:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/4c9d8effea8ec09a/high-immune-infiltration-predicts-worse-outcomes-in-bevacizumab-treated-ovarian-cancer-patients 2025-11-18T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/00fd208dab01bfd4/genesis-medtech-and-national-university-health-system-launch-four-year-ai-partnership-to-transform-surgical-care 2025-11-18T05:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/92e8f60a09392d37/70-year-old-blood-pressure-drug-hydralazine-shows-promise-against-aggressive-brain-tumors 2025-11-18T05:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/1475a169617848fa/microdose-cannabis-extract-shows-promise-in-slowing-cognitive-decline-in-alzheimer-s-patients 2025-11-18T03:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/15c449c8f9ff31f4/art-501-shows-promise-in-phase-2a-trial-for-autism-spectrum-disorder-treatment 2025-11-18T01:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/b906a721fb6c29a5/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-oncology-pipeline 2025-11-18T01:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/f5eb5de8ac421cf4/cincinnati-children-s-opens-expanded-gene-and-cell-therapy-manufacturing-center-to-accelerate-clinical-trials 2025-11-18T01:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/c6fc6eedf63e4703/terray-therapeutics-achieves-drug-discovery-milestone-with-bristol-myers-squibb-using-ai-native-emmi-platform 2025-11-18T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/c000ebc1c4ee11a6/fda-approves-komzifti-as-first-once-daily-oral-menin-inhibitor-for-relapsed-npm1-mutated-aml 2025-11-18T01:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/c384d03ba404979b/federal-judge-approves-purdue-pharma-s-7-4-billion-opioid-settlement 2025-11-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc52aeb5598f675a/aclipse-therapeutics-partners-with-mayo-clinic-for-phase-2-trial-of-first-disease-modifying-gastroparesis-treatment 2025-11-17T21:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/f174a840d7ec6b7c/dry-amd-market-set-for-significant-growth-through-2034-as-novel-therapies-advance-in-clinical-development 2025-11-17T21:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/f9c5a447850a96b2/scynexis-secures-35-million-nih-grant-to-advance-next-generation-antifungal-therapeutics 2025-11-17T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/50c4c1c6296486e9/protara-therapeutics-to-present-phase-2-tara-002-data-for-bcg-naive-bladder-cancer-patients-at-suo-meeting 2025-11-17T21:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/2e69a46773eeb1f2/azurity-pharmaceuticals-acquires-sebela-s-bowel-prep-franchise-as-sebela-advances-gerd-drug-tegoprazan-to-fda-submission 2025-11-17T21:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/34d235b4e079c14b/raphael-pharmaceutical-files-patent-for-thc-free-cannabinoid-therapy-targeting-rheumatoid-arthritis 2025-11-17T21:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/54b80da3b3d73c48/delhi-high-court-allows-natco-pharma-to-continue-cyantraniliprole-insecticide-sales-despite-fmc-patent-dispute 2025-11-17T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/533dc1fc372d1046/astrazeneca-and-sun-pharma-partner-to-expand-access-to-hyperkalaemia-treatment-in-india 2025-11-17T21:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/2d041e7dd9500d48/abbvie-s-lupron-depot-receives-health-canada-approval-for-new-6-month-dosing-option-in-advanced-prostate-cancer 2025-11-17T21:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/d98998761a7bd8aa/nerivio-wearable-device-shows-no-tachyphylaxis-in-3-year-migraine-study 2025-11-17T21:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/c7f19eba53ba7f70/is4s-secures-direct-to-phase-ii-sbir-contract-for-advanced-fireset-system-development 2025-11-17T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/b578ad9a12d814f5/fda-approves-first-perjeta-biosimilar-as-shanghai-henlius-and-organon-secure-interchangeable-status 2025-11-17T21:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/34148f4711e7eb55/nih-grant-terminations-disrupt-383-clinical-trials-affecting-over-74000-participants 2025-11-17T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/dc424660f343667b/crispr-gene-editing-reverses-chemotherapy-resistance-in-lung-cancer-by-targeting-nrf2 2025-11-17T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/b5722725de6c13ef/liquidia-s-yutrepia-achieves-commercial-success-with-51-7m-q3-sales-attracting-major-biotech-fund-investment 2025-11-17T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/fb73ac83e008d878/imbria-pharmaceuticals-secures-extended-series-b-funding-to-advance-first-in-class-cardiovascular-therapy-ninerafaxstat 2025-11-17T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/6265dade23d1aca5/4d-molecular-therapeutics-appoints-kristian-humer-as-cfo-as-company-advances-phase-iii-retinal-disease-programs 2025-11-17T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/09f9b151dc162edc/omeros-secures-240m-novo-nordisk-deal-as-narsoplimab-approaches-fda-approval-for-tatma 2025-11-17T17:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/973f08a1e0b74573/profluent-bio-partners-with-rsrt-to-develop-ai-designed-gene-editors-for-rett-syndrome 2025-11-17T17:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/2c02de8897f5f965/novo-nordisk-slashes-wegovy-and-ozempic-prices-for-cash-paying-patients 2025-11-17T17:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c5e0e27b77df8e5/acumen-pharmaceuticals-initiates-open-label-extension-study-for-alzheimer-s-drug-sabirnetug 2025-11-17T17:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/822f1d736c7740a2/acuitas-therapeutics-advances-next-generation-lipid-nanoparticle-technology-with-enhanced-potency-and-targeted-delivery 2025-11-17T17:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/6af3bce23d40b574/recode-therapeutics-advances-phase-2-trial-of-inhaled-cftr-mrna-therapy-rct2100-combined-with-ivacaftor-for-cystic-fibrosis 2025-11-17T17:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/e7a61083b4e2a4ff/masimo-wins-634-million-patent-verdict-against-apple-over-heart-rate-monitoring-technology 2025-11-17T17:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/14fbe89abc0c9463/angiex-raises-31-million-to-advance-first-in-class-nuclear-delivered-adc-agx101-through-phase-1-trial 2025-11-17T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/a484a0cb674de5b7/oceanic-stroke-phase-3-trial-advances-factor-xia-inhibitor-asundexian-for-secondary-stroke-prevention 2025-11-17T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/2a103b66dd1652b1/biotheryx-completes-enrollment-in-phase-1a-trial-of-first-in-class-cdk4-6-degrader-btx-9341-for-hr-her2-breast-cancer 2025-11-17T17:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/835890e44a4e346a/broken-string-biosciences-appoints-new-ceo-to-commercialize-gene-editing-safety-platform 2025-11-17T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/e53ed28bdbb9b639/artios-pharma-raises-115m-series-d-to-advance-dna-damage-response-cancer-therapies 2025-11-17T17:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/6d93806845b26fc4/biolinerx-secures-key-patent-for-glix1-cancer-therapy-covering-over-90-of-cancer-types 2025-11-17T17:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/a4becfb2da096c32/ohio-state-university-launches-400000-psychedelic-crisis-training-program-for-healthcare-professionals 2025-11-17T17:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/205b1a161d171b93/adaptimmune-undergoes-major-leadership-restructuring-following-nasdaq-delisting-and-asset-divestiture 2025-11-17T17:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/3481751b3a9ae6c3/johnson-johnson-acquires-halda-therapeutics-for-3-05-billion-to-strengthen-cancer-pipeline 2025-11-17T17:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/b33197121005dac0/scottish-brain-sciences-opens-third-clinical-research-center-in-aberdeen-to-advance-alzheimer-s-early-detection-studies 2025-11-17T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/74b834c1a8f0a9cf/artios-pharma-raises-115m-series-d-to-advance-next-generation-dna-damage-repair-cancer-therapies 2025-11-17T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/c0a7bd15f991c4ee/pluristyx-secures-1-4m-from-breakthrough-t1d-to-develop-universal-immune-cloaked-cell-line-for-type-1-diabetes-therapies 2025-11-17T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/7951460e83030f03/biorestorative-secures-fda-type-b-meeting-to-discuss-accelerated-approval-pathway-for-brtx-100-stem-cell-therapy 2025-11-17T17:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/a55743e205f44112/merus-and-halozyme-partner-to-develop-subcutaneous-formulation-of-petosemtamab-for-cancer-treatment 2025-11-17T17:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/03053bbd5aacfa64/who-approves-international-name-for-anixa-s-novel-car-t-therapy-targeting-ovarian-cancer 2025-11-17T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/8b8a81e2b3503c10/ema-launches-streamlined-process-to-fast-track-critical-medicines-and-vaccines-for-public-health-threats 2025-11-17T17:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/41dba08129e6d9c4/galmed-reports-promising-triple-drug-combination-for-gastrointestinal-cancers 2025-11-17T17:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/fa2f5fd317d3c4b9/solve-therapeutics-secures-120-million-to-advance-next-generation-adc-platform-for-solid-tumors 2025-11-17T17:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/578d4f772271bf79/pfizer-launches-cgrp-receptor-antagonist-rimegepant-for-migraine-treatment-in-india 2025-11-17T17:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/9ff8c26c73315a23/eu-funded-transcan-3-project-advances-personalized-t-cell-therapy-for-esophageal-cancer 2025-11-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a764cfcd3bcce9d3/nxera-pharma-announces-strategic-restructuring-with-15-workforce-reduction-to-focus-on-gpcr-pipeline 2025-11-17T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/7c0cc251a5ed4d3d/accession-therapeutics-doses-first-patient-in-phase-1-trial-of-novel-tumor-activated-viral-immunotherapy-trocept-01 2025-11-17T13:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/e320f0b93c9c03d3/itm-receives-fda-fast-track-designation-for-itm-94-diagnostic-agent-in-clear-cell-renal-cell-carcinoma 2025-11-17T13:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/34b264b8571c666f/ziihera-demonstrates-superior-efficacy-in-phase-3-trial-for-her2-positive-gastroesophageal-cancer 2025-11-17T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/9db94eda2850be92/switching-from-ibrutinib-to-zanubrutinib-maintains-efficacy-and-safety-in-waldenstrom-macroglobulinemia-patients 2025-11-17T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/b41287a27624e454/world-s-first-lung-cancer-prevention-vaccine-lungvax-receives-ps2-06-million-for-phase-i-clinical-trial 2025-11-17T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/3c03c91ee8491ff2/kazakhstan-s-anti-cancer-drug-targeting-kras-mutant-tumors-advances-to-phase-2026-clinical-trials 2025-11-17T13:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/d505f0c25386015c/captain-t-cell-secures-eur20-million-to-advance-next-generation-tcr-t-therapies-for-solid-tumors 2025-11-17T09:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/6450550f9a6081fb/agomab-s-ontunisertib-achieves-primary-safety-endpoint-in-first-in-class-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-11-17T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/ca892baa269dfd89/ybrain-launches-enhanced-at-home-electronic-depression-treatment-device-with-62-8-remission-rate 2025-11-17T09:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/78de86a135556483/sandoz-launches-first-fda-approved-multiple-sclerosis-biosimilar-tyruko-in-us-market 2025-11-17T09:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/9db37616c0a8290a/european-regulators-recommend-approval-of-incyte-s-minjuvi-for-relapsed-follicular-lymphoma 2025-11-17T09:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/7462686336e9f3d0/formycon-achieves-technical-proof-of-similarity-for-dupilumab-biosimilar-fyb208-targeting-20-billion-market 2025-11-17T09:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/43da2f3891582cde/nice-initiates-appraisals-for-two-cancer-immunotherapies-sasanlimab-bcg-combination-and-cemiplimab-adjuvant-treatment 2025-11-17T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/4342d5d921a82b83/wellscare-expands-iaso-wearable-cold-laser-therapy-to-thailand-through-strategic-partnership 2025-11-17T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/1e820587210db0df/bioxyne-secures-1-7m-scottish-government-funding-to-establish-uk-medicinal-cannabis-manufacturing-facility 2025-11-17T05:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/afb8fe0ba349c4d4/spravato-receives-fda-approval-as-first-monotherapy-for-treatment-resistant-depression 2025-11-17T05:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/e3e26c16de53cb59/golexanolone-shows-promise-as-early-disease-modifying-treatment-for-parkinson-s-disease 2025-11-17T03:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/118e5b5a2b115f98/annovis-bio-s-buntanetap-halts-cognitive-decline-in-parkinson-s-patients-shows-strongest-effect-in-amyloid-co-pathology-subgroup 2025-11-17T02:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3cf233d49b5693a/korean-biotech-platforms-drive-record-13-5-billion-in-technology-exports 2025-11-17T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/30f16c2b29022d65/crispr-cas9-gene-editing-shows-promise-for-treating-collagen-disorders 2025-11-17T01:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/c632eb339f11053e/epirium-bio-gains-fda-alignment-for-phase-2b-trial-of-first-in-class-sarcopenia-treatment-mf-300 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2b76798fc8d737c/pulsed-field-ablation-demonstrates-superior-efficacy-and-safety-profile-in-landmark-sham-controlled-trial-and-real-world-registry 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/040b51b31f4d5f9d/ivonescimab-receives-china-approval-for-egfr-mutated-nsclc-demonstrates-superior-efficacy-across-multiple-cancer-types 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe36b3e7353241e0/pharmather-secures-exclusive-rights-to-long-acting-injectable-ketamine-technology-for-treatment-resistant-depression 2025-11-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a8f35792f3771102/duke-health-reports-100-survival-rate-in-20-year-breast-cancer-vaccine-trial 2025-11-16T17:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/c4847077cc38509d/fda-grants-accelerated-approval-for-elevidys-gene-therapy-first-treatment-for-duchenne-muscular-dystrophy 2025-11-16T17:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/1fe96fc54ee36983/tumor-infiltrating-lymphocyte-therapy-shows-promise-in-advanced-melanoma-with-sustained-response-rates 2025-11-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f1c2c80f73e486d/zhongsheng-pharmaceutical-advances-pediatric-angladivir-granules-to-phase-iii-for-influenza-a-treatment 2025-11-16T13:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/550e5bc5ce69a507/cdsco-orders-dr-reddy-s-to-revise-vonoprazan-phase-iv-trial-protocol-over-inadequate-sample-size 2025-11-16T09:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/efb75dae43fb5f2b/aav-delivered-sirna-therapy-shows-promise-for-targeting-mucus-overproduction-in-asthma 2025-11-16T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/7ebb719b1b0f267a/obagi-medical-presents-pivotal-hyaluronic-acid-filler-data-at-asds-meeting-demonstrating-non-inferiority-to-juvederm-voluma 2025-11-16T09:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/00c214b128d819e7/pharvaris-reports-92-4-reduction-in-hereditary-angioedema-attacks-with-deucrictibant-in-long-term-study 2025-11-16T05:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/f56128abe5b8ae9d/engineered-aav-variants-show-10-fold-improvement-in-vascular-gene-delivery 2025-11-16T01:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/e98f11636452512f/nad-supplement-shows-early-promise-for-long-covid-fatigue-and-brain-fog-in-clinical-trial 2025-11-16T01:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/b590e634437512aa/brainxell-s-bxt-110-shows-promising-preclinical-results-for-parkinson-s-disease-cell-therapy 2025-11-16T01:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/4b7f3f6ec0665621/facet-life-sciences-and-xcancer-form-strategic-partnership-to-accelerate-theranostic-drug-development 2025-11-16T01:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/dc4071b77f0c5b9a/maxx-orthopedics-secures-fda-clearance-for-two-advanced-orthopedic-implant-systems 2025-11-16T01:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/740c53d1a87167bf/curevac-reports-eur371-6-million-net-income-following-gsk-partnership-and-strategic-restructuring 2025-11-15T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/d2c173c94709f930/fda-rejects-uniqure-s-amt-130-gene-therapy-data-for-huntington-s-disease-bla-submission 2025-11-15T21:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/4ed4fcb9965e112c/mangoceuticals-launches-direct-access-programs-for-zepbound-and-wegovy-through-eli-lilly-and-novo-nordisk-partnerships 2025-11-15T17:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/1764c8a5cf1c346b/trinity-biotech-partners-with-bioinformatics-company-to-advance-epicapture-prostate-cancer-test 2025-11-15T17:20:20+00:00 hourly 0.9 https://trial.medpath.com/news/1ac0826b69ab332e/curis-to-present-emavusertib-clinical-data-in-cns-lymphoma-at-society-for-neuro-oncology-meeting 2025-11-15T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/c8aec662dfd383ad/gates-foundation-awards-13-5-million-to-slash-monoclonal-antibody-costs-from-100-to-10-per-gram 2025-11-15T13:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/399fcf40a32b853b/tb-alliance-to-present-phase-2-results-for-sorfequiline-next-generation-tb-drug-candidate 2025-11-15T09:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/eda5fb65fab534ec/trevi-therapeutics-advances-chronic-cough-drug-haduvio-toward-phase-3-trials-with-extended-cash-runway-through-2028 2025-11-15T09:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/bfe9e0f3af71259c/gate-bioscience-raises-65-million-series-b-to-advance-novel-oral-molecular-gate-therapies-into-clinical-trials 2025-11-15T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/3359dc313dd81a0e/windtree-therapeutics-strengthens-patent-portfolio-for-heart-failure-drug-istaroxime-with-international-approvals 2025-11-15T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/8a59a276d7f34d9a/biomimetic-mrna-delivery-system-achieves-20-fold-improvement-in-tumor-targeting-for-colorectal-cancer 2025-11-15T05:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/2f48e40458cd43ea/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-15T01:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/4d7f4429f5eec769/curative-surgery-after-immunotherapy-reduces-death-risk-by-85-in-advanced-liver-cancer 2025-11-15T01:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/04f5c80a87e64ca9/magnetic-nanoparticles-enhance-amphotericin-b-delivery-against-leishmaniasis-with-reduced-toxicity 2025-11-15T01:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/85e58758c6c514a1/enzymit-and-cosun-achieve-world-s-first-pilot-scale-cell-free-hyaluronic-acid-production 2025-11-15T01:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/0c92cd5130acd1cb/orasis-pharmaceuticals-expands-qlosi-access-with-new-starter-packs-following-strong-market-adoption 2025-11-14T21:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/c00defc222c72d14/biotron-s-bit-hbv001-shows-superior-antiviral-activity-against-hepatitis-b-compared-to-standard-therapy 2025-11-14T21:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/265d7fe8e62072e2/revolutionary-car-t-therapy-shows-promise-for-autoimmune-disease-treatment 2025-11-14T17:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/a3c36a7960b93f36/anavex-life-sciences-shares-plummet-50-following-ema-rejection-of-alzheimer-s-drug-blarcamesine 2025-11-14T17:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/1e94b6bb0cb7765b/fortress-biotech-reports-strong-q3-2025-results-with-strategic-asset-sales-and-pipeline-advances 2025-11-14T17:27:02+00:00 hourly 0.9 https://trial.medpath.com/news/4fd602bef52e7132/general-proximity-partners-with-daiichi-sankyo-on-multi-target-oncology-collaboration-using-omnitac-platform 2025-11-14T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/43be8003f20ecc4f/third-arc-bio-partners-with-adagene-to-develop-masked-cd3-t-cell-engagers-for-solid-tumor-treatment 2025-11-14T17:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/682f18c7816d89d6/samson-clinical-completes-enrollment-for-phase-iii-sublingual-minoxidil-trial-in-male-pattern-hair-loss 2025-11-14T17:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/ed6298359eb33cb1/mhra-approves-leqembi-iv-maintenance-therapy-as-additional-treatment-option-for-alzheimer-s-disease 2025-11-14T17:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/cc3c3607ed95d6ed/bristol-myers-squibb-and-j-j-halt-phase-3-trial-of-blood-thinner-milvexian-in-acute-coronary-syndrome 2025-11-14T17:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/6941bbff447ad360/singapore-launches-phase-iii-of-national-precision-medicine-programme-to-enroll-400000-patients 2025-11-14T17:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/3360f752007124a3/zimmer-biomet-receives-fda-clearance-for-enhanced-rosa-knee-robotic-surgery-system 2025-11-14T17:20:26+00:00 hourly 0.9 https://trial.medpath.com/news/45cc842b1fbd8f8c/european-regulators-recommend-approval-for-waskyra-gene-therapy-for-rare-wiskott-aldrich-syndrome 2025-11-14T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/65f830cfadd6bd01/ema-recommends-first-gene-therapy-for-wiskott-aldrich-syndrome 2025-11-14T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/382e519622b73ced/sas-launches-clinical-acceleration-platform-to-streamline-drug-development-and-regulatory-submissions 2025-11-14T17:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/8b6987b170909527/biocon-explores-4-5-billion-merger-of-biologics-unit-with-parent-company-as-ipo-alternative 2025-11-14T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e886239a2582af8/medicxi-closes-eur500m-fund-v-to-accelerate-asset-centric-biotech-investments 2025-11-14T13:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/1ff81c62669ce598/boost-pharma-advances-stem-cell-therapy-bt-101-for-osteogenesis-imperfecta-with-positive-two-year-data-and-4-4m-funding 2025-11-14T13:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/cd1ff6ea81c46c79/stat-inhibitor-pipeline-expands-with-22-drugs-across-18-companies-targeting-cancer-and-inflammatory-diseases 2025-11-14T13:22:59+00:00 hourly 0.9 https://trial.medpath.com/news/4737bf1748906e55/appili-therapeutics-secures-40-million-niaid-contract-for-antifungal-vaccine-development 2025-11-14T13:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/e475fe5e63adaea1/lundbeck-seeks-asian-market-approval-for-vyepti-migraine-prevention-therapy 2025-11-14T13:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/4fed57822351e416/matisse-pharmaceuticals-advances-m6229-sepsis-treatment-with-positive-120-hour-infusion-trial-results 2025-11-14T13:20:39+00:00 hourly 0.9 https://trial.medpath.com/news/7af0dee264ec4746/fda-approves-five-breakthrough-therapies-for-gastrointestinal-cancers-in-first-half-of-2025 2025-11-14T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/5979df1f98c057ed/prism-biolab-achieves-first-milestone-in-oncology-drug-discovery-partnership-with-ono-pharmaceutical 2025-11-14T13:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/fa1eddc7fdbaf0f2/fda-approves-omeros-yartemlea-as-first-treatment-for-rare-post-transplant-blood-disorder-ta-tma 2025-11-14T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/85489eb0d98d110a/4teen4-pharmaceuticals-secures-eur55-million-to-advance-procizumab-in-cardiogenic-shock 2025-11-14T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/d8ac8fe3c35f58ee/diamyd-medical-s-phase-3-type-1-diabetes-trial-clears-final-safety-review-ahead-of-march-2026-readout 2025-11-14T09:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/d491f706215cba61/shield-therapeutics-initiates-phase-ii-trial-of-accrufer-for-pulmonary-arterial-hypertension-in-japan 2025-11-14T09:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/d369fec9093b4c6e/biopharma-job-market-recovery-expected-by-late-2026-despite-current-downturn 2025-11-14T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/7d5ab419eb11d365/palatin-technologies-advances-melanocortin-based-obesity-pipeline-with-18-2m-funding-and-boehringer-ingelheim-partnership 2025-11-14T05:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/48dff63b97523833/merck-nears-3-3-billion-acquisition-of-cidara-therapeutics-for-breakthrough-influenza-treatment 2025-11-14T05:21:54+00:00 hourly 0.9 https://trial.medpath.com/news/6eb14855550e6475/dare-bioscience-advances-women-s-health-pipeline-with-near-term-revenue-launch-and-positive-phase-3-data 2025-11-14T05:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/fe7762f1d686781c/cognito-therapeutics-and-wvu-launch-first-brain-health-collaboratory-to-accelerate-neurotherapy-development 2025-11-14T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/a692595cbe3a0dde/tandemai-secures-22m-series-a-extension-to-advance-ai-powered-drug-discovery-platform 2025-11-14T05:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce97d6cfa57b2ba5/regeneron-announces-2-billion-manufacturing-expansion-in-new-york-creating-1000-jobs 2025-11-14T05:18:46+00:00 hourly 0.9 https://trial.medpath.com/news/8f3d77cb782dcda2/repare-therapeutics-agrees-to-1-82-per-share-acquisition-by-xenotherapeutics 2025-11-14T04:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3a83a02d9f77320/imagenebio-advances-anti-ox40-antibody-img-007-with-protocol-amendment-for-phase-2b-atopic-dermatitis-trial 2025-11-14T01:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/96c5a1d665af16a4/pfizer-reduces-biontech-stake-by-55-as-covid-vaccine-partnership-evolves 2025-11-14T01:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/3ba4eec3298b98fc/bryet-us-secures-patent-for-nanoporous-silicon-drug-delivery-platform-targeting-cancer-treatment-resistance 2025-11-14T01:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/6e1cf742ca20ebcc/fennec-pharmaceuticals-announces-public-offering-to-fund-debt-reduction-and-operations 2025-11-14T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/2fa5747dd2a98be7/nanobiotix-advances-curadigm-nanoprimer-platform-with-new-patent-filings-and-promising-vaccine-combination-data 2025-11-14T01:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/45b63db239367ddb/amneal-secures-fda-approval-for-first-generic-iohexol-injection-challenging-652-million-market 2025-11-14T01:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/79de851cb0dcc3bb/magnetic-microrobots-successfully-navigate-blood-vessels-for-targeted-drug-delivery-in-large-animal-studies 2025-11-14T01:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/d15621285db0cbf6/iraq-launches-major-cancer-drug-manufacturing-initiative-with-50-price-reduction-target 2025-11-14T01:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/e4f01ee4eaa96939/delve-bio-s-metagenomic-sequencing-test-shows-promise-for-faster-meningitis-encephalitis-diagnosis 2025-11-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/89e02fbe79a7c9da/merck-acquires-cidara-therapeutics-for-9-2-billion-to-advance-revolutionary-flu-prevention-drug 2025-11-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e7093a512bd1138/integra-lifesciences-receives-fda-510-k-clearance-for-cusa-clarity-ultrasonic-surgical-aspirator-system-in-cardiac-surgery 2025-11-13T21:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/3f412217fa638f3c/salarius-pharmaceuticals-and-decoy-therapeutics-complete-strategic-merger-to-advance-ai-driven-peptide-conjugate-platform 2025-11-13T21:29:28+00:00 hourly 0.9 https://trial.medpath.com/news/bffa19139c9df83c/breakthrough-antibody-marv16-shows-40-100-fold-increased-potency-against-marburg-virus 2025-11-13T21:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/bc995047550ffcd5/fda-grants-fast-track-designation-to-fog-001-first-in-class-b-catenin-inhibitor-for-desmoid-tumors 2025-11-13T21:26:36+00:00 hourly 0.9 https://trial.medpath.com/news/27b696cc1ab74812/eureka-s-artemis-car-t-cells-demonstrate-16-fold-superior-tumor-infiltration-in-neuroblastoma-study 2025-11-13T21:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/fb2d914563a31b9c/legend-biotech-opens-31000-square-foot-r-d-facility-in-philadelphia-to-advance-car-t-cell-therapy-innovation 2025-11-13T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/fa3bb87ebb3eeab5/fda-approved-prostate-cancer-drugs-show-promise-against-acute-myeloid-leukemia-in-preclinical-studies 2025-11-13T21:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/b3e16bcb1c4b971d/korro-bio-abandons-lead-rna-editing-drug-after-clinical-disappointment-cuts-34-of-staff 2025-11-13T21:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/7bebc6c7e3cfc614/zealand-pharma-halts-obesity-drug-dapiglutide-development-amid-crowded-glp-1-market 2025-11-13T21:22:32+00:00 hourly 0.9 https://trial.medpath.com/news/3034add4fe1832d5/hypoglycemia-therapeutics-market-shows-robust-pipeline-activity-with-16-molecules-in-development 2025-11-13T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/e1797d4d77b89ae0/pfizer-completes-10-billion-metsera-acquisition-to-enter-obesity-market-with-monthly-glp-1-portfolio 2025-11-13T21:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/c6cbd0f761c0179f/fda-approves-first-interchangeable-biosimilar-to-pertuzumab-for-her2-positive-breast-cancer 2025-11-13T21:20:08+00:00 hourly 0.9 https://trial.medpath.com/news/20c6c9da9736fe4a/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-129m-targeting-rare-cancer-treatment 2025-11-13T21:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/15c693c8bd6fa0fe/icotec-receives-fda-clearance-for-cmore-ct-system-expanding-blackarmor-carbon-peek-technology-to-cervicothoracic-spine 2025-11-13T21:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/760af02b9fe06ef4/fda-approves-kura-oncology-s-komzifti-for-npm1-mutated-aml-with-competitive-safety-advantage 2025-11-13T17:30:39+00:00 hourly 0.9 https://trial.medpath.com/news/63683c016b5a23f4/gilead-s-investigational-hiv-single-tablet-regimen-meets-primary-endpoint-in-phase-3-artistry-1-trial 2025-11-13T17:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/cef0746129b584ac/isofol-medical-secures-european-patent-protection-for-cancer-drug-arfolitixorin-until-2043 2025-11-13T17:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/007db93fd87a5d73/medicus-pharma-receives-uk-regulatory-approval-to-expand-phase-2-basal-cell-carcinoma-study 2025-11-13T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/3040398a5eeb1774/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-285-million-to-advance-novel-adc-for-rare-cancer 2025-11-13T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/8cfd074cc34b2cae/austrian-study-challenges-routine-tablet-crushing-for-stroke-patients-with-dysphagia 2025-11-13T17:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/33eda7fe518a846c/aeon-biopharma-secures-22-million-funding-to-advance-botox-biosimilar-abp-450-development 2025-11-13T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/e55ffa988e22914f/aeon-biopharma-achieves-100-amino-acid-sequence-match-with-botox-in-biosimilar-development 2025-11-13T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/ae36fde9eafa75eb/withings-receives-fda-clearance-for-beamo-multi-function-health-device-combining-ecg-stethoscope-and-thermometer 2025-11-13T17:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/814cebd892339975/century-therapeutics-unveils-immune-evasive-ipsc-beta-islet-therapy-for-type-1-diabetes 2025-11-13T17:20:16+00:00 hourly 0.9 https://trial.medpath.com/news/46191c88451cd21a/beacon-biosignals-secures-86m-series-b-to-advance-ai-driven-brain-health-diagnostics 2025-11-13T17:20:14+00:00 hourly 0.9 https://trial.medpath.com/news/da67ca13c1ce4d84/viagra-shows-promise-for-reversing-genetic-hearing-loss-through-nitric-oxide-pathway 2025-11-13T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/f926b9ff00b1d12c/ingenus-pharmaceuticals-launches-first-generic-version-of-premarin-tablets-after-fda-approval 2025-11-13T17:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/fca0fc17a0fb45a3/inflammasome-therapeutics-partners-with-mass-general-s-healey-als-center-to-test-novel-neuroinflammation-drug-k9 2025-11-13T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d3b4c17efdb4d11/traditional-chinese-medicine-flavonoid-extract-shows-promise-for-stroke-recovery-through-enhanced-angiogenesis 2025-11-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93b81d93ad9dbb5a/phio-pharmaceuticals-achieves-100-tumor-clearance-in-skin-cancer-trial-as-fda-accepts-ph-762-development-protocol 2025-11-13T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/eaedd874c25e2320/day-one-biopharmaceuticals-acquires-mersana-therapeutics-for-25-per-share-in-285-million-deal 2025-11-13T13:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/b021a5aad76aee43/zealand-pharma-reports-strong-q3-2025-results-as-obesity-drug-pipeline-approaches-key-data-readouts 2025-11-13T13:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/082c4f802244d743/fda-accepts-itm-s-new-drug-application-for-177lu-edotreotide-in-gastroenteropancreatic-neuroendocrine-tumors 2025-11-13T13:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/08d7000843799856/t-therapeutics-raises-91-million-series-a-to-advance-first-in-class-tcr-cd3-bispecifics-for-cancer-and-autoimmune-disease 2025-11-13T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/013a1b3701b0da2c/adicon-acquires-crown-bioscience-for-204-million-to-create-global-laboratory-services-platform 2025-11-13T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/216fe5ef4a561f37/zydus-amplitude-s-robotic-surgical-system-andy-receives-ce-mark-approval-for-european-market 2025-11-13T13:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/3ea9dbf3581b26d1/scripta-therapeutics-raises-12m-to-target-transcription-factors-for-disease-modifying-therapies 2025-11-13T13:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/a81637ffd5c24dad/envirogold-global-achieves-99-55-gold-recovery-in-phase-3-metallurgical-testing-of-mine-tailings-reprocessing-technology 2025-11-13T13:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/ed88d2ec767b1af1/mursla-bio-partners-with-global-pharma-to-develop-ai-driven-biomarkers-for-mash-precision-medicine 2025-11-13T13:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/364c67f01ef2c0ca/charm-therapeutics-advances-ai-discovered-menin-inhibitor-chm-029-to-overcome-aml-drug-resistance 2025-11-13T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/253f5806121faa04/low-dose-colchicine-shows-promise-in-reducing-heart-attacks-and-strokes-in-cardiovascular-disease-patients 2025-11-13T09:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/a9d9b3af861c3459/revolutionary-nanoplatforms-combine-ferroptosis-and-immunotherapy-to-transform-tumor-microenvironment 2025-11-13T09:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/bdf85ee8a6c14c18/neoadjuvant-cemiplimab-plus-sbrt-improves-2-year-disease-free-survival-in-resectable-hepatocellular-carcinoma 2025-11-13T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/0b3c94395da98971/rage-biotech-raises-a-29-million-series-a-to-advance-rna-therapeutics-for-chronic-inflammatory-diseases 2025-11-13T09:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/b1831c0861737fa0/korro-bio-s-rna-editing-drug-shows-promise-but-falls-short-of-efficacy-targets-in-alpha-1-antitrypsin-deficiency-trial 2025-11-13T05:23:21+00:00 hourly 0.9 https://trial.medpath.com/news/4f7d443071c0a8f2/nhs-approves-glofitamab-for-earlier-treatment-of-aggressive-blood-cancer 2025-11-13T05:20:28+00:00 hourly 0.9 https://trial.medpath.com/news/6bb8ee07f3c0bc04/apellis-reports-5-year-data-showing-syfovre-delays-geographic-atrophy-progression-by-1-5-years 2025-11-13T01:27:11+00:00 hourly 0.9 https://trial.medpath.com/news/2cbd55cbd53a75bd/health-canada-approves-kyzatrex-oral-testosterone-therapy-expanding-treatment-options-for-canadian-men 2025-11-13T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/2ba9b53d648ab9bb/wrn-inhibitors-enter-clinical-development-phase-as-precision-oncology-market-expands 2025-11-13T01:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/324ed9016ec5e905/indero-develops-3-day-microdosing-method-to-accelerate-topical-drug-development-using-gene-expression-analysis 2025-11-13T01:23:31+00:00 hourly 0.9 https://trial.medpath.com/news/05762349f267061a/macrogenics-halts-lorigerlimab-development-in-prostate-cancer-secures-75m-in-partnership-proceeds 2025-11-13T01:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/5aaaa313d5ee73bd/eupraxia-s-ep-104gi-shows-sustained-clinical-remission-in-eosinophilic-esophagitis-patients-at-52-weeks 2025-11-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/806d2b54f0d240c6/fda-grants-accelerated-approval-for-semaglutide-in-mash-treatment-but-equity-gaps-persist-in-clinical-trials 2025-11-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/463fa1cac5f8f6f9/bristol-myers-squibb-and-sarah-cannon-research-institute-expand-strategic-collaboration-to-accelerate-cancer-clinical-trials 2025-11-12T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/d0ff3168e961c9be/genezen-partners-with-humane-genomics-to-manufacture-novel-oncolytic-virus-therapy-for-pediatric-liver-cancer 2025-11-12T21:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/8cfe2470cf11ef89/lupin-manufacturing-solutions-launches-dedicated-oncology-block-at-vizag-facility-to-expand-cdmo-capabilities 2025-11-12T21:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/ba50ad6d58e1a3b1/federal-cannabis-crackdown-validates-mmj-international-s-fda-compliant-pharmaceutical-approach 2025-11-12T21:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/32dcf15e96ad4c02/trinity-college-dublin-develops-needle-free-nasal-vaccine-that-blocks-whooping-cough-transmission 2025-11-12T21:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/c1608ddd69295f83/modulight-biotherapeutics-raises-12-2m-to-advance-optogenetic-therapy-for-neurological-disorders 2025-11-12T21:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/1806a5834de1d645/abbvie-terminates-3-5-billion-calico-partnership-after-11-years-cuts-100-jobs 2025-11-12T21:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/9e727d0b10154bd8/phase-iii-trybeca-1-trial-shows-eryaspase-fails-to-improve-survival-in-advanced-pancreatic-cancer 2025-11-12T21:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/dce38a020b924d32/durvascc-trial-evaluates-durvalumab-chemotherapy-combination-for-rare-extrapulmonary-small-cell-carcinoma 2025-11-12T21:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/b52464e979a50922/single-dose-malaria-treatment-achieves-93-cure-rate-in-phase-3-trial-matching-standard-multi-day-therapy 2025-11-12T21:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/5ae08ae4e1ce7168/neurogene-advances-ngn-401-gene-therapy-for-rett-syndrome-with-positive-interim-data-and-registrational-trial-progress 2025-11-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c0a23f01f53fa34/aprea-therapeutics-reports-promising-early-clinical-data-for-dna-damage-response-inhibitors 2025-11-12T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/b4620b1731fd62f5/eli-lilly-drops-cvs-drug-plan-for-employees-following-weight-loss-drug-coverage-dispute 2025-11-12T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/430c63f60b0af34b/sequential-car-t-cell-therapy-and-autologous-stem-cell-transplant-shows-97-survival-rate-in-ph-negative-b-all 2025-11-12T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/32f37fa9f33f7f1f/vietnam-approves-russian-pembrolizumab-biosimilar-for-cancer-treatment 2025-11-12T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/2c57d97422e63e26/real-world-evidence-shows-potential-survival-advantage-for-apalutamide-over-abiraterone-in-metastatic-prostate-cancer 2025-11-12T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/43a41794996f8d2d/dyno-therapeutics-and-trisk-bio-form-strategic-manufacturing-partnership-to-accelerate-gene-therapy-development 2025-11-12T17:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/daa1718a6047cf13/eirgenix-secures-152m-licensing-deal-with-sandoz-for-her2-positive-breast-cancer-biosimilar 2025-11-12T17:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/ca83eeec4b5d3da4/xoma-royalty-reports-strong-q3-2025-results-with-multiple-strategic-acquisitions-and-key-pipeline-milestones 2025-11-12T17:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/927e12ebdddbf661/seed-therapeutics-receives-china-nmpa-clearance-for-st-01156-molecular-glue-degrader-in-rare-cancer-trial 2025-11-12T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/59d45ddbb24ab6f8/remedy-plan-therapeutics-achieves-breakthrough-with-first-safe-nampt-inhibitor-rpt1g-for-blood-cancers 2025-11-12T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/434e49b082d7e89b/indivi-secures-chf-15-million-to-advance-alzheimer-s-biomarker-discovery-platform 2025-11-12T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/af03136d6805e4bb/bostongene-and-kyoto-university-partner-to-develop-ai-powered-biomarkers-for-esophageal-cancer-treatment 2025-11-12T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/4c55931e00336d4e/pepgen-secures-u-s-patent-for-pgn-edodm1-advancing-myotonic-dystrophy-type-1-treatment 2025-11-12T17:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/abfca278fa557df8/elite-pharmaceuticals-secures-fda-approval-for-generic-ropinirole-extended-release-tablets-for-parkinson-s-disease 2025-11-12T17:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/1ff44cd86e33febb/fda-accelerated-approval-pathway-under-scrutiny-as-sarepta-seeks-traditional-approval-despite-failed-dmd-trial 2025-11-12T17:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/88a5b3b83e3e2d78/fgf18-emerges-as-promising-therapeutic-target-for-post-traumatic-osteoarthritis-through-foxn2-pathway 2025-11-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b883f54ec51e2d63/longeveron-secures-u-s-patent-for-stem-cell-treatment-of-aging-related-frailty 2025-11-12T14:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa8629865a86ce2c/apellis-syfovre-shows-sustained-efficacy-in-five-year-geographic-atrophy-study-delaying-disease-progression-by-1-5-years 2025-11-12T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/72892e176631ca01/ovid-therapeutics-advances-ov329-to-phase-2-following-positive-safety-results-in-drug-resistant-epilepsy-program 2025-11-12T13:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/d0f10c3a4d895e59/india-launches-first-car-t-manufacturing-training-program-to-build-cell-and-gene-therapy-expertise 2025-11-12T13:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/e80547e73917d31b/adocia-files-patent-for-adoxlong-platform-to-extend-peptide-therapy-duration-to-monthly-injections 2025-11-12T13:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/2a27b1369874f637/nanoform-receives-european-commercial-cgmp-license-advances-multiple-nanoformulated-drug-programs 2025-11-12T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/76814f133ed95d30/nuformix-receives-fda-clarification-request-for-orphan-drug-designation-of-tranilast-in-idiopathic-pulmonary-fibrosis 2025-11-12T13:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/3029e6d02ecce843/mhra-approves-betaglue-therapeutics-yntradose-clinical-trial-for-unresectable-pancreatic-cancer 2025-11-12T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1140cf3993475918/abeona-therapeutics-advances-zevaskyn-gene-therapy-commercialization-for-rare-skin-disease 2025-11-12T11:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c8a62a9736b9b85/australian-blood-test-shows-promise-for-personalizing-parp-inhibitor-therapy-in-ovarian-cancer 2025-11-12T09:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/e388a8b627105eef/dbv-technologies-completes-patient-enrollment-in-pivotal-vitesse-phase-3-trial-for-peanut-allergy-patch 2025-11-12T09:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/3c76056ffc0d0e14/indian-pharma-companies-win-major-generic-drug-supply-contracts-in-china-s-healthcare-market 2025-11-12T09:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/988659fd85f949e8/fda-clears-magstim-magnetic-stimulation-device-for-chronic-pain-treatment 2025-11-12T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ca7a45c06a808a4/cogent-biosciences-raises-475-3-million-to-advance-bezuclastinib-for-systemic-mastocytosis 2025-11-12T06:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/5c99fd082c187a5e/earlier-hepatitis-c-cure-assessment-shows-promise-for-high-risk-populations 2025-11-12T05:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/c953d386cb2995f2/abl-bio-secures-2-6-billion-deal-and-180-million-strategic-investment-from-eli-lilly-for-grabbody-platform 2025-11-12T05:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/637ebe32ec457bc5/pathkey-and-armstrong-clinical-partner-to-enhance-early-phase-trial-success-through-ai-powered-design 2025-11-12T05:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/420f292c227955b2/real-world-study-shows-equivalent-survival-outcomes-for-abiraterone-and-enzalutamide-in-veterans-with-metastatic-prostate-cancer 2025-11-12T05:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/6ee593152621bc00/medley-therapeutics-advances-first-in-human-gene-therapy-trial-for-heart-regeneration-after-safety-milestone 2025-11-12T05:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/0d4f2bd979b6c07b/dyno-therapeutics-unveils-ai-engineered-aav-vector-dyno-bn8-for-muscle-gene-therapy-with-25-fold-dose-reduction 2025-11-12T05:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/a336be1081ee0300/lecanemab-clears-alzheimer-s-plaques-but-fails-to-restore-brain-s-waste-clearance-system 2025-11-12T01:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/466abc8d4f9f7b82/metagenomi-advances-mgx-001-hemophilia-a-gene-therapy-with-curative-activity-in-primates 2025-11-12T01:23:19+00:00 hourly 0.9 https://trial.medpath.com/news/4a6146826576cb8c/curegene-s-cg-0416-shows-superior-fat-loss-while-preserving-muscle-in-preclinical-obesity-studies 2025-11-12T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/839b2e940e1ab90e/university-hospital-tubingen-launches-depeca-1-trial-testing-enfortumab-vedotin-avelumab-combination-for-advanced-penile-cancer 2025-11-12T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/73c638ba77e46bb4/metagenomi-s-mgx-001-gene-therapy-achieves-curative-factor-viii-levels-in-hemophilia-a-preclinical-study 2025-11-12T01:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/00f6404ef90b94a0/fda-recalls-generic-vyvanse-due-to-failed-dissolution-tests-affecting-therapeutic-efficacy 2025-11-12T01:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/f978d04696d7211b/visby-medical-expands-access-to-first-fda-authorized-at-home-pcr-test-for-stis-through-quest-and-labcorp-partnerships 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/30416eaf240b7b67/sellas-life-sciences-reports-promising-phase-2-results-for-sls009-in-venetoclax-resistant-aml-at-ash-2025 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/32fa6167096585a3/longeveron-secures-canadian-patent-for-stem-cell-therapy-targeting-aging-related-frailty-and-heart-disease 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/89d4b313a95169cc/adia-med-receives-irb-approval-for-autism-clinical-trial-combining-stem-cells-with-glutathione 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae2b193e2b0f4ad9/usa-rare-earth-completes-strategic-acquisition-of-less-common-metals-secures-european-rare-earth-supply-chain 2025-11-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/84697e68325fde56/cnipa-invalidates-tofacitinib-sustained-release-patent-over-lack-of-inventive-step 2025-11-11T21:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/fe0ebf23d000f9c2/tel-aviv-university-researchers-discover-rna-based-gene-therapy-that-reverses-als-nerve-damage 2025-11-11T21:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/8a8a2c517428669e/neuphoria-therapeutics-receives-5-20-per-share-acquisition-offer-from-lynx1-master-fund-following-phase-iii-trial-failure 2025-11-11T21:21:56+00:00 hourly 0.9 https://trial.medpath.com/news/db2e0d637b503dfc/engene-s-gene-therapy-achieves-63-complete-response-rate-in-pivotal-bladder-cancer-trial 2025-11-11T21:21:42+00:00 hourly 0.9 https://trial.medpath.com/news/b3924e535d373934/quoin-pharmaceuticals-surges-on-fda-orphan-drug-designation-for-rare-skin-disorder-treatment 2025-11-11T21:20:27+00:00 hourly 0.9 https://trial.medpath.com/news/21065a204e11018d/new-report-analyzes-biotechnology-licensing-trends-and-deal-structures-from-2020-2025 2025-11-11T21:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/a088a8f8936c4980/south-africa-launches-first-domestically-developed-cholera-vaccine-trials 2025-11-11T21:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/37af590ecfd49cea/coramitug-phase-2-data-published-in-circulation-as-novo-nordisk-advances-phase-3-cleopattra-trial-for-attr-cardiomyopathy 2025-11-11T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/fb39367ab25c06e9/cancer-drug-venetoclax-shows-100-efficacy-in-preventing-als-progression-in-preclinical-study 2025-11-11T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/c8d1b8f9a215cfcd/irhythm-s-zio-long-term-ecg-monitoring-shows-consistent-performance-across-asian-and-non-asian-populations 2025-11-11T17:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/5054094cfbfdada0/novel-monoclonal-antibody-f9h4-prevents-cd16a-b-shedding-to-enhance-nk-cell-mediated-cancer-immunotherapy 2025-11-11T17:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/c8096ec51a0ef271/muna-therapeutics-initiates-phase-1-trial-of-novel-oral-trem2-agonist-mna-001-for-early-alzheimer-s-disease 2025-11-11T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/803a0fde8b3fd808/pediatric-atopic-dermatitis-trials-shift-focus-to-patient-centered-outcomes 2025-11-11T17:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/10b01d6a9c65f647/merck-partners-with-kenyan-firm-to-establish-local-production-of-pediatric-schistosomiasis-treatment 2025-11-11T17:21:14+00:00 hourly 0.9 https://trial.medpath.com/news/e3ff1e4c992e6ece/engene-holdings-reports-63-complete-response-rate-in-phase-2-bladder-cancer-gene-therapy-trial 2025-11-11T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/1319cdaa85e2aa61/quoin-pharmaceuticals-achieves-high-concentration-topical-rapamycin-formulations-for-rare-vascular-malformations 2025-11-11T17:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/6dc42fed6981ce61/repair-biotechnologies-reports-atherosclerotic-plaque-regression-with-rep-0003-in-preclinical-study 2025-11-11T17:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/b83b7b6ea1aad6d7/mabwell-s-anti-il-11-antibody-9mw3811-becomes-world-s-first-il-11-therapeutic-to-enter-phase-ii-for-pathological-scarring 2025-11-11T17:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/a9930e631df930da/allurion-advances-toward-fda-approval-with-zero-finding-inspections-and-5m-financing 2025-11-11T17:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/44721370d161d4be/satralizumab-demonstrates-17-4-reduction-in-pulmonary-vascular-resistance-in-biomarker-selected-pah-patients 2025-11-11T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/30d6c9d95045dabe/real-world-car-t-therapy-outcomes-show-promise-despite-higher-toxicity-rates-in-diverse-patient-population 2025-11-11T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/b23f94e9222e7c2a/servier-india-launches-subsidized-biomarker-testing-initiative-for-aml-and-cholangiocarcinoma-patients 2025-11-11T13:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/e56bf36841db4c64/zydus-lifesciences-secures-first-drug-approval-in-china-for-venlafaxine-er-capsules 2025-11-11T13:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/deb2b4398c70c505/mgi-tech-partners-with-south-africa-to-launch-110k-human-genome-program-and-deploy-africa-s-first-dnbseq-t7-sequencer 2025-11-11T13:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/cee0e28b46baf241/mytomorrows-secures-29-million-to-expand-ai-powered-platform-for-pre-approval-treatment-access 2025-11-11T13:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/cb57d7cb1d2cdcfc/granules-life-sciences-receives-first-us-fda-approval-for-hyderabad-manufacturing-facility 2025-11-11T13:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/bd89459ca072b805/ai-adoption-accelerates-in-clinical-trials-as-industry-tackles-rising-complexity-and-white-space-inefficiencies 2025-11-11T12:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/55ad696374479c96/belenos-reports-promising-phase-1b-results-for-bel512-bispecific-in-atopic-dermatitis 2025-11-11T05:20:24+00:00 hourly 0.9 https://trial.medpath.com/news/6a76f1801b03a95c/shilpa-medicare-s-extended-release-ondansetron-injection-shows-superior-efficacy-in-phase-3-cinv-trial 2025-11-11T05:19:58+00:00 hourly 0.9 https://trial.medpath.com/news/a8faeb9d6d764ec2/experimental-drug-m102-shows-promise-in-slowing-motor-neurone-disease-progression 2025-11-11T05:19:19+00:00 hourly 0.9 https://trial.medpath.com/news/9c4c30daed2bc4a4/pcsk9-inhibitor-alirocumab-safely-reduces-cholesterol-by-50-in-heart-transplant-patients 2025-11-11T01:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/989618b4212ec672/neurocrine-s-nbi-1070770-fails-to-meet-primary-endpoint-in-phase-ii-major-depressive-disorder-trial 2025-11-11T01:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/a37190e75bf92c44/quince-therapeutics-receives-positive-safety-review-for-ataxia-telangiectasia-treatment-in-phase-3-trial 2025-11-11T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/962d1a25ea4a12ba/sublingual-epinephrine-film-shows-comparable-safety-and-efficacy-in-pediatric-patients 2025-11-11T01:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/c2661a9efe82b3b0/capsovision-seeks-fda-breakthrough-device-designation-for-non-invasive-pancreatic-cancer-screening-capsule 2025-11-11T01:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/f85777cf0c36e9aa/ivermectin-safety-trial-confirms-drug-can-be-safely-used-in-children-as-small-as-5-kg 2025-11-10T21:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/b7482880aceca4e6/vittoria-biotherapeutics-to-present-first-in-human-car-t-data-for-t-cell-lymphoma-at-ash-2025 2025-11-10T21:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/5dfe9e9ceea29967/tizona-s-ttx-080-shows-dual-immune-activation-in-advanced-solid-tumors-advances-to-phase-1b-colorectal-cancer-trial 2025-11-10T21:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/169b044d19fb5530/galecto-completes-285m-acquisition-of-damora-therapeutics-to-advance-rare-blood-cancer-pipeline 2025-11-10T21:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/7de90a13f0311c8f/orbus-therapeutics-reports-positive-phase-3-stellar-trial-results-for-eflornithine-in-recurrent-idh-mutant-astrocytoma 2025-11-10T21:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/979b087a1f50e2b5/amgen-expands-patent-litigation-against-denosumab-biosimilar-developers-in-latest-bpcia-filings 2025-11-10T21:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/948610282490dbd6/williams-cancer-institute-demonstrates-complete-tumor-resolution-with-combined-pulsed-electrical-field-ablation-and-intratumoral-immunotherapy 2025-11-10T21:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/72e0994e805444bd/imaging-biometrics-completes-phase-i-trial-of-gallium-maltolate-for-recurrent-glioblastoma 2025-11-10T21:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/779626e932d2aeb4/zelenectide-pevedotin-demonstrates-promising-safety-and-efficacy-in-advanced-solid-tumors 2025-11-10T21:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/0108a2d987d657d5/athos-therapeutics-partners-with-xeptiva-to-deploy-ai-platform-for-veterinary-vaccine-biomarker-discovery 2025-11-10T21:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/9d525f70a23673ab/ascend-advanced-therapies-develops-proprietary-enhancers-boosting-aav-production-yields-up-to-3-fold 2025-11-10T21:24:20+00:00 hourly 0.9 https://trial.medpath.com/news/8e5f910ba88923b9/evidium-secures-22m-series-a-to-advance-transparent-healthcare-ai-platform 2025-11-10T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/2b6ef6b1dff98031/eco-animal-health-advances-toward-eu-approval-for-poultry-vaccine-targeting-mycoplasma-synoviae 2025-11-10T21:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/55c4ee2d6f9a8105/fda-grants-fast-track-designation-to-avenzo-s-avzo-1418-for-egfr-mutated-nsclc 2025-11-10T21:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/797d77a8a8cb8a59/kenya-partners-with-africa-medicines-agency-to-accelerate-drug-registration-and-boost-local-manufacturing 2025-11-10T21:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/1fea9de800782467/ps1-5m-connect-target-trial-launches-precision-medicine-approach-for-childhood-brain-cancer 2025-11-10T21:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/ce8c4c4bad1a98b2/transition-bio-and-voyager-therapeutics-partner-to-develop-small-molecule-tdp-43-inhibitors-for-als-and-frontotemporal-dementia 2025-11-10T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/f75c67ecc18c63e9/tuxedo-2-trial-shows-prasugrel-outperforms-ticagrelor-in-diabetic-patients-after-stent-placement 2025-11-10T17:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/f5632ec6862653d1/johns-hopkins-achieves-5-pancreatic-cancer-recurrence-rate-with-intraoperative-radiation-targeting-baltimore-triangle 2025-11-10T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/29f682a25bb22be0/inflarx-s-oral-c5ar-inhibitor-inf904-shows-biologic-like-efficacy-in-phase-2a-trials-for-hidradenitis-suppurativa-and-chronic-spontaneous-urticaria 2025-11-10T17:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/e71eab416c4cbeb9/galectin-therapeutics-belapectin-shows-sustained-antifibrotic-effects-in-mash-cirrhosis-through-36-months 2025-11-10T17:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ffb1ecf12a3f7004/semaglutide-shows-cardiovascular-benefits-in-hiv-patients-with-fatty-liver-disease-in-slim-liver-trial 2025-11-10T17:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/8ca89d66f6f7a23d/voyager-therapeutics-advances-multi-modal-neurotherapeutics-pipeline-with-novel-neuroshuttle-platform-and-tdp-43-collaboration 2025-11-10T17:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/c95c0ab8cb60f4ac/reviva-secures-european-patent-for-brilaroxazine-in-pulmonary-fibrosis-treatment 2025-11-10T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/40a38e2b7fd412c4/liscure-biosciences-launches-phase-2-trial-of-first-in-class-lb-p8-for-primary-sclerosing-cholangitis 2025-11-10T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/58c2b3f31e2fa81a/geneseeq-s-pantrkaretm-receives-nmpa-approval-as-china-s-first-ngs-based-pan-solid-tumor-companion-diagnostic-for-ntrk-gene-fusions 2025-11-10T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/93b2652d65b06904/mannkind-discontinues-phase-3-trial-of-nebulized-clofazimine-for-ntm-lung-disease-due-to-futility 2025-11-10T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/eff053610c4b2872/tiumbio-s-dual-tgf-b-vegf-inhibitor-tosposertib-shows-70-6-response-rate-in-head-and-neck-cancer-trial 2025-11-10T17:20:19+00:00 hourly 0.9 https://trial.medpath.com/news/0bf2f381d85658f9/armata-pharmaceuticals-commissions-state-of-the-art-cgmp-phage-manufacturing-facility-to-advance-antibiotic-resistant-infection-treatments 2025-11-10T17:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/7f9f667efa7c3d23/nurix-therapeutics-strengthens-board-with-former-pfizer-and-seagen-executive-roger-dansey 2025-11-10T17:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/33ca3128f37242b0/vascarta-s-sto-1-achieves-67-survival-rate-in-preclinical-glioblastoma-study 2025-11-10T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/09cb42e12d0ecebb/tandem-diabetes-secures-fda-approval-for-mobi-android-app-stock-surges-20 2025-11-10T17:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/97250eae35242616/novartis-opens-new-radioligand-therapy-manufacturing-facility-in-california-as-part-of-23-billion-us-expansion 2025-11-10T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbc28e7e69a035e3/venus-concept-receives-fda-510-k-clearance-for-venus-nova-multi-application-aesthetic-platform 2025-11-10T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/79bc22b50393dfe3/akeso-s-ak135-shows-promise-for-chemotherapy-induced-neuropathy-in-preclinical-studies 2025-11-10T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/63b20c4aab4084ba/poly-hf-trial-polypill-strategy-improves-heart-function-and-reduces-hospitalizations-in-heart-failure-patients 2025-11-10T17:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/a5c9257b2ba79ec5/sino-biopharm-and-meditrust-health-partner-to-advance-drug-insurance-integration-model-in-china 2025-11-10T13:23:10+00:00 hourly 0.9 https://trial.medpath.com/news/2bc4acd59dd14c5b/leucid-bio-s-novel-car-t-therapy-leu011-shows-proof-of-concept-in-solid-tumors-with-encouraging-safety-profile 2025-11-10T13:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/577ea737fb36bf88/uk-high-court-clears-path-for-alvotech-s-eylea-biosimilar-manufacturing-ahead-of-patent-expiry 2025-11-10T13:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/ba5f26edc28f0cac/rona-therapeutics-rn0361-sirna-demonstrates-93-apoc3-reduction-in-phase-1-trial-for-severe-hypertriglyceridemia 2025-11-10T13:21:08+00:00 hourly 0.9 https://trial.medpath.com/news/fd0866152700c2c1/glenmark-receives-china-approval-for-ryaltris-nasal-spray-first-fixed-dose-combination-for-allergic-rhinitis 2025-11-10T13:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/32acff7f6bcba391/simcere-s-il-2-mutant-fusion-protein-sim0278-advances-to-phase-ii-trial-for-atopic-dermatitis 2025-11-10T13:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/e16027615c4d077e/exact-sciences-blood-test-shows-seven-fold-improvement-in-early-liver-cancer-detection-over-standard-ultrasound 2025-11-10T13:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/446c1acb713c7cea/revvity-partners-with-eli-lilly-to-democratize-ai-drug-discovery-through-tunelab-platform-integration 2025-11-10T13:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/a85c8cb4270b5de5/innate-pharma-receives-fda-clearance-for-phase-3-trial-of-lacutamab-in-cutaneous-t-cell-lymphoma 2025-11-10T09:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/68db055ab9e353c7/avingtrans-subsidiary-adaptix-receives-fda-510-k-clearance-for-revolutionary-3d-orthopaedic-imaging-system 2025-11-10T09:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/4cb108b6861d4b43/chong-kun-dang-showcases-three-promising-drug-candidates-at-major-u-s-medical-conferences 2025-11-10T05:22:42+00:00 hourly 0.9 https://trial.medpath.com/news/d3b0dc09e01e347d/innovent-and-sanegenebio-report-promising-phase-1-results-for-ibi3016-sirna-hypertension-therapy 2025-11-10T05:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/b62a373ceaa37cae/targeted-vitamin-d3-supplementation-cuts-heart-attack-recurrence-risk-by-50-in-clinical-trial 2025-11-10T01:21:23+00:00 hourly 0.9 https://trial.medpath.com/news/6d39798393283cec/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients-over-two-years 2025-11-10T01:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/ae661297d81f7950/calidi-biotherapeutics-advances-cld-401-oncolytic-virus-therapy-toward-ind-filing-in-q4-2026 2025-11-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/50cfa894b5e04be1/visionary-holdings-launches-medical-grade-stem-cell-anti-aging-product-line-in-asia 2025-11-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7fc7994da93a8a0/glp-1-receptor-agonists-show-no-increased-pancreatitis-risk-in-high-triglyceride-patients-study-finds 2025-11-09T21:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/10d4c6ad26dc67c5/george-medicines-reports-sustained-blood-pressure-control-with-widaplik-triple-combination-therapy-in-52-week-extension-study 2025-11-09T17:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/cc09b626232ab17d/metformin-shows-promise-in-reducing-atrial-fibrillation-recurrence-after-catheter-ablation 2025-11-09T17:19:31+00:00 hourly 0.9 https://trial.medpath.com/news/3e5dac89ca189055/scientists-engineer-human-stomach-cells-to-produce-insulin-for-type-1-diabetes-treatment 2025-11-09T17:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/6dde321362e910c6/scientists-discover-novel-antibiotic-class-with-potent-activity-against-drug-resistant-bacteria 2025-11-09T17:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/97bd2e136411c523/metformin-may-blunt-exercise-benefits-in-diabetes-prevention-rutgers-study-finds 2025-11-09T17:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/adbfdb8ef1be6b01/novel-nomogram-predicts-survival-outcomes-for-advanced-nsclc-patients-receiving-immunotherapy-beyond-progression 2025-11-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/17f58faef47219b6/zinzino-acquires-mexican-health-company-sanki-for-8-million-to-expand-americas-distribution-network 2025-11-09T13:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/668c04a08bef4455/sibeprenlimab-demonstrates-54-proteinuria-reduction-in-largest-phase-3-iga-nephropathy-trial 2025-11-09T09:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/9e6c4a7037b58ddc/fda-investigates-byheart-baby-formula-after-13-infants-hospitalized-with-botulism-across-10-states 2025-11-09T01:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/9ccc1b9fff224dc2/vtama-cream-shows-49-5-response-rate-in-pediatric-atopic-dermatitis-patients-without-comorbidities 2025-11-09T01:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/ad8fc1a8b8ff6cbe/shortened-dual-anticoagulation-therapy-after-stent-placement-shows-equal-efficacy-with-reduced-bleeding-risk-in-afib-patients 2025-11-09T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/873bfb4c53325654/optigo-biotherapeutics-appoints-industry-veteran-andreas-wallnofer-to-board-as-long-acting-anti-vegf-advances-to-ind-enabling-studies 2025-11-08T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/1e2670550a862fb1/fish-oil-supplementation-reduces-cardiovascular-events-by-43-in-dialysis-patients-pisces-trial-shows 2025-11-08T21:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/6a57048fa452e2ee/pelthos-therapeutics-acquires-xepi-for-antibiotic-resistant-impetigo-treatment-and-secures-18-million-financing 2025-11-08T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/16b4b86676df6701/chlorotoxin-based-car-t-cell-therapy-demonstrates-safety-and-feasibility-in-recurrent-glioblastoma-phase-1-trial 2025-11-08T21:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/539d7616631751fd/hot-flashes-treatment-pipeline-expands-with-15-novel-therapies-from-leading-pharmaceutical-companies 2025-11-08T21:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/88d656bb62e58e86/sotagliflozin-shows-significant-benefits-in-heart-failure-patients-with-preserved-ejection-fraction-without-diabetes 2025-11-08T21:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/dc2e76da79f98cb3/ohsu-researchers-develop-novel-cancer-drug-su212-targeting-triple-negative-breast-cancer 2025-11-08T21:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/0142d972b8ba3d87/triple-receptor-agonist-dr10624-shows-promise-in-phase-ii-trial-for-severe-hypertriglyceridemia 2025-11-08T21:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/ec073cc9ad841379/sanegenebio-partners-with-eli-lilly-in-1-2-billion-rnai-collaboration-for-metabolic-diseases 2025-11-08T21:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/688f9bc7bae1b1a1/sparsentan-shows-superior-proteinuria-reduction-in-pediatric-fsgs-patients-compared-to-standard-care 2025-11-08T21:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/97e57a9c1ed327ae/immunic-s-vidofludimus-calcium-shows-promising-ms-data-as-phase-3-trials-approach-2026-readout 2025-11-08T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca17e4076e00e8d3/inflarx-stock-surges-67-5-ahead-of-critical-phase-2a-trial-results-for-inf904 2025-11-08T17:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/5a8c7899ceae75ad/inka-health-publishes-framework-to-enable-cross-border-use-of-real-world-evidence-in-oncology 2025-11-08T17:20:40+00:00 hourly 0.9 https://trial.medpath.com/news/9596a2b74fc6f0dc/ccp-approves-getz-group-s-acquisition-of-novartis-pakistan-in-major-pharmaceutical-transaction 2025-11-08T17:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/3fe6dae84bf16ffa/phase-ii-trial-shows-promise-for-toripalimab-flot-combination-in-gastric-cancer-with-peritoneal-metastasis 2025-11-08T17:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/5e86e5e14c311256/onconaut-therapeutics-secures-2-5m-nih-grant-to-advance-chd1l-inhibitors-for-metastatic-colorectal-cancer 2025-11-08T13:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/88927728ea2a683f/hikma-launches-first-us-biosimilar-starjemza-seventh-ustekinumab-alternative-to-enter-market 2025-11-08T09:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/aac36079f97dde70/kardigan-s-ataciguat-shows-promise-in-phase-2-trial-for-moderate-calcific-aortic-valve-stenosis 2025-11-08T05:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/8986a595bdc37b4e/ng101-shows-promise-in-phase-2-trial-for-glp-1-induced-nausea-and-vomiting 2025-11-08T01:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/5590bb787a6c41f1/fda-places-clinical-hold-on-tenaya-s-gene-therapy-trial-for-rare-heart-disease 2025-11-08T01:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/01639a6ea7c48e71/taiho-pharmaceutical-challenges-uspto-over-1-billion-lytgobi-patent-extension-denial 2025-11-08T01:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/f36fcf270b69fb94/inflarx-to-report-phase-2a-results-for-oral-c5ar-inhibitor-inf904-in-hidradenitis-suppurativa-and-chronic-spontaneous-urticaria 2025-11-08T01:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/e3b6b37965999588/novel-nano-formulated-cbd-delivers-rapid-neuropathic-pain-relief-in-preclinical-study 2025-11-08T01:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/35d8c94708182c5e/real-world-study-identifies-patient-subtypes-most-likely-to-benefit-from-cobenfy-first-new-schizophrenia-drug-in-50-years 2025-11-08T01:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/974a5626f8b2440f/synchron-secures-200m-series-d-to-commercialize-brain-computer-interface-platform 2025-11-08T01:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/18bcfbe39fb73f42/assembly-biosciences-reports-positive-phase-1b-results-for-next-generation-hepatitis-b-capsid-assembly-modulator-abi-4334 2025-11-07T21:27:02+00:00 hourly 0.9 https://trial.medpath.com/news/8357f55293298486/urogen-pharma-gains-fda-pathway-for-ugn-103-as-zusduri-achieves-record-early-demand 2025-11-07T21:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/a8e21c84fe9d6089/immunocore-s-imc-i109v-shows-promising-antiviral-activity-in-phase-1-hepatitis-b-trial 2025-11-07T21:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/5cdcff7aaf0fdbee/rutgers-cancer-institute-reports-breakthrough-t-cell-therapies-achieve-long-term-remission-in-hpv-associated-cancers 2025-11-07T21:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/e72da0fc4de4ab9d/proton-pump-inhibitors-linked-to-worse-breast-cancer-outcomes-in-large-international-study 2025-11-07T21:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/8c0b538728363ccc/optigo-biotherapeutics-advances-long-acting-anti-vegf-therapy-xpk-640-toward-ind-enabling-studies 2025-11-07T21:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/6ac54fdf7246c8a3/tissue-regenix-faces-urgent-funding-crisis-as-regenerative-medicine-company-seeks-ps5m-to-avoid-insolvency 2025-11-07T21:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/34e5e62ff6795d2d/takeda-s-mezagitamab-shows-sustained-kidney-protection-18-months-after-treatment-in-iga-nephropathy 2025-11-07T21:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/6e3523b701380f02/cranial-technologies-brings-fda-cleared-doc-band-r-infant-head-reshaping-treatment-to-china-following-nmpa-approval 2025-11-07T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/235f6c781046dc19/gilead-s-trodelvy-fails-primary-endpoint-in-first-line-hr-her2-metastatic-breast-cancer-trial 2025-11-07T17:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/bd82f4377d375d9a/indapta-s-allogeneic-nk-cell-therapy-shows-promising-activity-in-heavily-pretreated-multiple-myeloma-patients 2025-11-07T17:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/5f5b350edc8dc275/sequential-pd-1-inhibitors-show-promise-as-consolidation-therapy-following-cd19-car-t-treatment-in-relapsed-nhl 2025-11-07T17:23:34+00:00 hourly 0.9 https://trial.medpath.com/news/4cbde1aa18bc1b96/genvivo-reports-positive-phase-1-results-for-gen2-off-the-shelf-cancer-immunotherapy 2025-11-07T17:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/e282f2f161df03f6/metavia-s-vanoglipel-shows-dual-benefits-in-mash-phase-2a-trial-with-significant-hba1c-reduction-and-liver-improvements 2025-11-07T17:22:30+00:00 hourly 0.9 https://trial.medpath.com/news/a9da82cbc9ff0013/stk-012-combination-shows-57-response-rate-in-pd-l1-negative-nsclc-phase-1-trial 2025-11-07T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/3b71b9ca3fedb7ed/io-biotech-unveils-promising-preclinical-data-for-next-generation-cancer-vaccines-targeting-tumor-microenvironment 2025-11-07T17:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/9a879a0477da739c/eledon-advances-kidney-transplant-drug-to-phase-iii-despite-missing-primary-endpoint-in-phase-ii-trial 2025-11-07T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/ec6516341fd6c12c/oncoinvent-launches-nok-130-million-rights-issue-to-advance-radspherin-radiopharmaceutical-therapy 2025-11-07T17:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/5258512fed98fc5d/abzena-and-mabqi-form-strategic-partnership-to-streamline-antibody-drug-development 2025-11-07T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/312937d3f2c2dbe2/brii-biosciences-combination-therapy-shows-promise-for-hepatitis-b-functional-cure-in-phase-2-study 2025-11-07T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/5c7e1160e754e4d0/iqirvo-shows-sustained-long-term-benefits-in-primary-biliary-cholangitis-with-novel-fatigue-mechanism-insights 2025-11-07T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/ae25e0bb3c53e873/shield-therapeutics-accrufer-receives-marketing-approval-in-south-korea-for-iron-deficiency-treatment 2025-11-07T13:21:53+00:00 hourly 0.9 https://trial.medpath.com/news/7029380a2935c2ac/biomunex-unveils-mait-engager-platform-data-at-sitc-2025-targeting-enhanced-cancer-immunotherapy-safety 2025-11-07T13:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/004c0cdb5b80abbc/lupus-nephritis-drug-market-transforms-with-targeted-therapies-as-unmet-medical-needs-drive-innovation 2025-11-07T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/db23d19cf8c15f8c/onchilles-pharma-receives-fda-clearance-for-first-in-class-elane-pathway-cancer-therapeutic-n17350 2025-11-07T11:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b371c37d3f47f2d/oncotelic-therapeutics-joint-venture-identifies-biomarker-signature-for-precision-mtor-inhibitor-therapy 2025-11-07T11:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/449a2c1389928046/aquestive-therapeutics-advances-global-regulatory-strategy-for-anaphylm-epinephrine-sublingual-film 2025-11-07T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/728ec95b13f9b4ef/esmo-2025-highlights-transformative-advances-in-cancer-treatment-adcs-move-to-earlier-disease-settings-while-ai-integration-accelerates 2025-11-07T09:58:37+00:00 hourly 0.9 https://trial.medpath.com/news/d6a3fa00e4a8492c/independent-vaccine-experts-launch-review-of-hepatitis-b-birth-vaccination-data-following-cdc-panel-delay 2025-11-07T09:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/354a367ffa9c26ab/mbx-biosciences-raises-150-million-to-advance-canvuparatide-into-phase-iii-trials 2025-11-07T09:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/d22bc7d07e6b14a1/japanese-consortium-develops-ai-powered-cancer-vaccines-targeting-dark-genome-antigens 2025-11-07T09:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/a22058523e8f19b1/oric-pharmaceuticals-publishes-breakthrough-research-on-brain-penetrant-egfr-inhibitor-enozertinib-for-lung-cancer 2025-11-07T05:23:26+00:00 hourly 0.9 https://trial.medpath.com/news/52370d2f5836ac97/trump-administration-announces-major-price-cuts-for-glp-1-weight-loss-drugs-through-trumprx-initiative 2025-11-07T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/46b9c8931a0f4259/canadian-researchers-develop-next-generation-car-t-therapy-targeting-solid-tumors-with-mesothelin 2025-11-07T05:21:27+00:00 hourly 0.9 https://trial.medpath.com/news/1c362b964bde993b/nj-bio-expands-translational-research-capabilities-through-l2p-research-labs-asset-acquisition 2025-11-07T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/9851ee7484484225/best-vascular-novoste-celebrates-25-years-of-fda-approved-vascular-brachytherapy-for-coronary-restenosis 2025-11-07T05:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/a7156db34f89d0fb/cardiff-oncology-reports-positive-phase-2-data-for-plk1-inhibitor-onvansertib-in-ras-mutated-colorectal-cancer 2025-11-07T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/655a34f2cc9100f4/pfizer-accelerates-pf-08634404-bispecific-development-with-multiple-phase-3-trials-following-1-25b-3sbio-deal 2025-11-07T01:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/dcb8a7670a5236e6/supremo-trial-shows-chest-wall-radiation-may-be-omitted-in-intermediate-risk-breast-cancer-without-compromising-survival 2025-11-07T01:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/cf7044122eeb0ad3/pliant-therapeutics-reports-promising-50-response-rate-for-pln-101095-in-checkpoint-resistant-solid-tumors 2025-11-07T01:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/2b8277db19bee50b/sutro-biopharma-receives-fda-clearance-for-stro-004-tissue-factor-adc-advances-dual-payload-platform 2025-11-07T01:21:49+00:00 hourly 0.9